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ABSTRACT
In this dissertation we describe methods for measuring infection relevant
biochemical analytes using radioluminescent and ultrasound luminescent materials. Films
and nanoparticles fabricated with europium doped gadolinium oxysulfide (Gd2O2S:Eu3+)
are used to quantitatively measure radiolabeled pharmaceutical concentration, specifically
tritium labeled vancomycin (3H-vancomycin). Europium and dysprosium doped strontium
aluminate is used to fabricate an ultrasound modulated, pH sensing film. These methods
are indicated for theranostic evaluation of implant associated infection. Bacterial biofilms
are inherently resistant to traditional antibiotic treatment and can coat biomedical implants.
These biofilm related infections are difficult or impossible to eradicate non-invasively. As
a result, implant coatings for early infection detection and prevention are a promising
avenue of research. Non-invasive measurement of drug release is an important metric for
development of effective treatment strategies because dosage must be sustained within a
therapeutic window to be effective. In vitro methods of evaluating drug release are unable
to replicate biological conditions and variability seen within patients. Furthermore, early
detection of implant associated infection can aid early diagnosis and treatment to mitigate
infection severity. For infection prevention, using a Gd2O2S:Eu3+ film we are able to
quantitatively measure antibiotic concentration at the implant surface, through 5 mm of
tissue. We also demonstrate proof of principle for application of this technique with
synthesized Gd2O2S:Eu3+

nanoparticles. For early detection of infection, we have

developed an ultrasound luminescent chemical imaging modality, and pH sensing film, to
map local acidosis due to bacterial biofilm growth at the implant surface.
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CHAPTER 1
INTRODUCTION

We describe methods for making chemical measurements, through biological
tissue, using radioluminescent materials. Specifically, we use europium doped gadolinium
oxysulfide (Gd2O2S:Eu) to monitor radiolabeled drug (3H-vancomycin) release from a
biomedical implant surface and demonstrate proof of principle to monitor release from
nanoparticle surfaces. To monitor pH at the implant surface, we use europium and
dysprosium doped strontium aluminate (SrAl2O4:Eu,Dy) paired with a pH sensitive dye.
These methods are demonstrated in relation to a model of implant associated infection, as
local acidosis is an indication of bacterial growth and vancomycin is a representative
pharmaceutical for the treatment of biofilm related infection. However, the developed
methods are intended for general application and depend on multiple factors for success.
These considerations include the mechanism of radioluminescence (confined to discussion
of inorganic crystals), the excitation source(s), interaction of luminescence with tissue, and
collection optics.

1.1 Photon Generation: Radioluminescence Excitation and Emission
Radioluminescent materials convert ionizing radiation, such as X-Ray or betaradiation, into visible light. These materials are used for a variety of applications that
require radiation detection (e.g., biomedical diagnostics, dosimetry, industrial inspection)
as well as for TV cathode-ray screens and fluorescent lighting.[1] The mechanism of
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scintillator radiation conversion to visible light begins with generation of electron-hole
pairs within a wide band gap material (inorganic crystal, in this case) following irradiation
with high energy photon(s) (<1 MeV). This interaction occurs primarily through Compton
scattering and the photoelectric effect. Compton scattered photons will often produce
multiple electron-hole pairs until the energy of the photon is completely dissipated or the
photon exits the crystal. The electron hole pairs then propagate throughout the crystal
structure, and eventually luminescence occurs via radiative recombination of the electron
and hole at luminescent centers (activators).[1] Activator ions introduce energy levels
within the forbidden gap and permit more efficient radiative recombination, producing
light in the visible range (Figure 1.1). Without luminescent activators, the return of an
electron to the valence band is inefficient (due to large band gap) and energy is typically
emitted via nonradiative recombination. If photons are emitted in this process, the energy
is too high to be in the visible range.[2] Even when luminescent activators are present crystal
defects (e.g., material point defects, grain boundaries, and surface flaws) can hinder
scintillator luminescence efficiency. The scintillator crystals discussed in this work are
Gd2O2S and SrAl2O4 doped with activators Eu3+, and Eu2+/Dy3+, respectively.[3–5]
Imaging luminescence through tissue requires optimization of various parameters
for success. Of the inherent radioluminescent material properties, some important
parameters to consider include light yield (quantum efficiency), radiation stopping power
(higher electron density=more stopping power), luminescence decay time, chemical
stability, spectral matching between luminescence emission and photon detector, and
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Figure 1.1. Scintillation process broken down into three steps: conversion of radiation to electron-hole pairs,
transport of electron-hole pairs throughout the lattice, and radiative recombination resulting in visible
luminescence.

linearity of response between incoming radiation and luminescence output. Of particular
interest is light yield, which can be defined by the following equation[6,7]:
𝛽𝑆𝑄
)
𝑔 [𝑒𝑉]

(1)

𝐿𝑌 = 4.35 × 105 (𝐸

Where β is the conversion efficiency of incoming radiation, Eg is the energy of
forbidden band gap, S is the transport efficiency of electron-hole pairs through the crystal
lattice, and Q is the efficiency of luminescence at emission centers. Typical band gap
energies for scintillation crystals range from <1 eV to several eV. To optimize
luminescence efficiency (Q), the activator ground electronic state must be above the
valence band for the host crystal, and the activator excited state must be below the
conduction band for the host crystal (see figure 1.1).[7] For example pure Gd2O2S crystal
has a band gap energy (Eg) of 4.6 eV, and the Eu3+ dopant most prominent luminescence
emission bands (electronic transitions 5D0 → 7Fj) occur due to 3.42 eV location of 4f states
within that bandgap range.[8–10] The inorganic phosphors used for sensor design throughout
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this dissertation emit luminescence with high efficiency (60,000 photons/MeV X-Ray for
bulk Gd2O2S:Eu3+). Overall, the luminescence efficiency and light yield is largely a
function of the material.
The excitation sources used for the methods described in this dissertation are
primarily beta-decay radiation (Emax=18 keV per decay for 3H), UV light (3-30 eV per
photon), and mechanical release of trapped electron-hole pairs after UV excitation via
mechanical ultrasound stimulation. Beta-particles interact with matter primarily via
ionization, electron orbital excitation, and bremsstrahlung X-Ray production (in cases with
high-energy beta emission in high atomic number absorbers).[7] Because beta-particles and
electrons have essentially equivalent mass, collisions result in significant transference of
kinetic energy and electron scattering. The resulting ionization of electrons often produces
secondary ionization by electrons ejected after primary collision with beta-particle.
For tritium (3H) beta-decay, range is limited to the area immediately surrounding
the radioactive isotope. For example, tritium decay is typically reported to carry a
1

maximum energy (Emax) of 18 keV, but average beta emission energy is closer to 3 𝐸𝑚𝑎𝑥
(~6 keV).[7] Given the energy of decay (E) in MeV, the range (R) in cm, of a beta particle
in a given medium is governed primarily by the density of the absorber (d) in g/cm3, and
can be described by[7,11]:
𝑅=

0.11(√1+22.4𝐸 2 −1)
𝑑

for 0 < E < 3 MeV

(2)

For 3H beta-decay in water, the range is expected to be between 0.4 and 4 µm. As
a result, radioluminescence emission is dependent on the concentration and proximity of
radiolabeled analyte (3H-vancomycin) to radioluminescent material (Gd2O2S:Eu3+).
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For mechanoluminescent materials in this dissertation (i.e., SrAl2O4:Eu2+/Dy3+),
UV light is used to “charge” the material. UV photons interact with the crystalline lattice,
and electron clouds of the atoms, via Compton scattering and the photoelectric effect. This
leads to ionization and production of electron-hole pairs (as described in section 1.1). The
radiative recombination of electron-hole pairs can be slow, even in the presence of activator
ions, when the absorbed photon exhibits intersystem crossing to an excited triplet state.
These “trapped” electrons can be released via mechanical stimulation.[5,12,13] As a result,
luminescence emission can be stimulated, point-by-point, using a focused ultrasound
beam. The mechanoluminescent properties of SrAl2O4:Eu2+/Dy3+ are combined with pH
sensitive dyes to map surface pH.

1.2 Photon Collection: Effect of Tissue and Optics for Light Detection
The first series of considerations for developing luminescence-based biosensors is
based upon photon generation. However, even when using high energy excitation and
materials that exhibit high quantum efficiency, the ability to collect and count emitted
photons is another important consideration. Absorption and scattering of light by biological
media detract from the overall luminescence intensity able to be collected. Once light
passes through tissue to the point where it is collected, the efficiency of collection optics
also has a dramatic effect.
Light interacts differently with different types of biological tissue. Tissues and
fluids can be categorized as strongly scattering (skin, blood, muscle, brain, etc.) or weakly
scattering (aqueous humor within the eye, cornea, etc.). Tissues containing intrinsic
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chromophores are going to absorb more light, in a wavelength dependent manner. For
example, tissue is most transparent to light within the near infrared region (NIR) because
biological components do not strongly absorb this spectral range.[14] In short, there are a
variety of factors that affect light propagation in tissue. The classical light propagation
model for biological tissues is based on radiative transport theory, which depends largely
on the total ballistic attenuation coefficient (µt) (equation 3) and angular distribution of
scattering [15,16]:
(3)

µ𝑡 = µ𝑎 + µ𝑠

Where µa (m-1) represents the absorption coefficient, and µs (m-1) is the scattering
coefficient. However, despite consideration of various tissue types, it is difficult to
generalize light behavior in tissue due to homogeneities inherent among living beings. As
a result, luminescence based biosensors typically need to have a reference to account for
tissue effects and non-uniformities, experimentally.[17–19] In addition, mechanical
indentation of tissue is occasionally appropriate to minimize thickness and increase photon
collection efficiency.[20]
Once luminescence has propagated through tissue, the collection efficiency of
optics is the next important consideration. Spectral sensitivity of the photon detector needs
to match the luminescence emission being collected. For example, traditionally a
photodiode is considered optimum for wavelengths in the green-red, while photomultiplier
detectors are more suitable for detection in the UV-blue spectral range. In recent years,
there has been substantial development of back illuminated, cooled, charge coupled devices
(CCD) that have wider wavelength range sensitivity.[1]
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1.3 Description of Dissertation
Chapter 1 provides a brief introduction to the phenomenon of radioluminescence,
which is important for the remainder of the dissertation, followed by a brief description of
the research reported in the following chapters.
Chapter 2 describes a method to image and quantify radiolabeled drug release from
biomedical implant surfaces using a radioluminescent, hydrophilic polyurethane composite
film. The technique is used to quantify tritium labeled vancomycin (3H-vancomycin)
release from a film of Gd2O2S:Eu. The method is performed through 5 mm porcine muscle
tissue to demonstrate feasibility for in vivo application. Luminescence images are acquired
using a supercooled charge coupled device (CCD) camera (In Vitro Imaging System –
small animal imager).
In chapter 3 we extended the work done in chapter 2 to provide proof of principle
for monitoring drug release using radioluminescent, sodium fluoride doped Gd2O2S:Eu
nanoparticles and radiolabeled vancomycin. Preliminary data is provided which
demonstrates a linear correlation between concentration of radiolabeled drug and
radioluminescent particles.
Chapter 4 describes the use of mechanoluminescent SrAl2O4:Eu/Dy polymer
composite films for mapping pH in complex biological tissue mimic. Images are acquired
as the sample is scanned, point-by-point, relative to a stationary pulsing ultrasound source
and liquid light guide collection optics.
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Chapter 5 contains overall conclusions and description of future directions for the
work described herein. Namely the combination of mechanoluminescent and
radioluminescent materials is proposed as an advantageous way to image drug release, and
incorporation of radioactive material with the mechanoluminescent film may provide an
alternative excitation source to UV for eventual in vivo application.
Finally, appendices A-C provide detailed explanation of the MATLAB scripts used
for image analysis throughout this work.
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CHAPTER 2
RADIOLUMINESCENCE IMAGING OF DRUG ELUTION
FROM BIOMEDICAL IMPLANTS

2.1 Abstract
We describe a method to noninvasively measure the concentration of radiolabeled
pharmaceuticals on modified drug-eluting biomedical implant surfaces. The implants are
coated with microphosphors and radiolabeled pharmaceuticals in a hydrophilic
polyurethane film. The drug molecules emit radiation which excites radioluminescence in
nearby phosphors; for drug released from the film, the radiation is absorbed by the
surrounding media and generates no light. We applied the technique to measuring betaemitting tritium-labeled vancomycin (3H-vancomycin) concentration on the surface of an
orthopedic plate. Bacteria can coat orthopedic implant surfaces and form biofilms which
are resistant to antibiotics and the host’s immune system. Antibiotic eluting implant
coatings are thus promising candidates for infection prevention and treatment.
Radioluminescence imaging permits surface-specific, noninvasive measurement of drug
concentration on implant surfaces, which is an important metric for developing effective
drug eluting coatings. The radioluminescence signal increases linearly with

3

H-

vancomycin concentration, with a limit of detection (LOD) of 9.6 nCi (0.35 pmol) without
tissue. We also monitored biomedically relevant drug release concentrations by spiking
unlabeled vancomycin with 3H-vancomycin. Using this technique, we achieve an LOD of
5.7 nmol through 0 mm of porcine tissue slices, and 38.7 nmol vancomycin through 5 mm
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porcine tissue slices. Despite light scattering, drug release and reference regions are
resolvable for non-invasive quantification.
2.2 Introduction
Over half of hospital acquired infections are associated with implanted medical
devices, and infections are hard to treat because bacteria can form biofilms on the device
surface that are resistant to antibiotics.[1,2] For example, around 5-10% of fracture fixation
surgeries result in infection with variation depending largely on injury severity, location,
time to surgery, diabetes, smoking, immune compromised states, revision of previously
infected implant, and other risk factors.[3] Hypothesized mechanisms for antibiotic
resistance in biofilms include a combination of nutrient limitation and slow growth,
quorum sensing, formation of persister cells, and poor antibiotic penetration.[1,2,4–6] The
minimum bactericidal concentration (MBC) for bacterial biofilms can be 10-1000 times
higher than that required to eradicate planktonic bacterial infections, which is difficult or
impossible to achieve in vivo.[7] As a result, there has been much research done to develop
infection-specific imaging techniques[8–11], as well as antibiotic-releasing implants for
prevention and treatment of bacterial biofilms on biomedical implants.[3,12–15] It is
important that the release profile be controlled to keep local drug concentration in the
therapeutic window and below toxic doses. A variety of methods are available to control
the release, and there is also interest in “smart” systems with release controlled by pH and
exogenous signals.[16] However, these techniques are typically difficult to evaluate in vivo,
especially with heterogeneous environments during infection at the implant surface.
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Figure 2.1. Radiopharmaceutical detection method using radioluminescent phosphors. A) Illustration of
fracture fixation plate coated with radioluminescent phosphor particles. B) Relative decay probability vs
energy of associated 3H beta particle emission. Mean energy of tritium decay is roughly 5.7 keV but can be
as high as 18 keV. C) Beta-decay range for 3H in water, calculated based on Emax.[38] Indicates required
proximity of radionuclide to radioluminescent phosphor particle for excitation and subsequent luminescence
emission spectrum of Gd2O2S:Eu3+ radioluminescent phosphors (inset).
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Assessing local drug release and/or accumulation is quite challenging for in vivo
applications. There have been numerous advances in non-invasive drug monitoring
techniques, including use of nanomaterials as therapeutic and diagnostic drug carriers [16–
19]

, electrical impedance[20], optical imaging[16,17,21–23], and magnetic resonance imaging

(MRI)[24,25]. However, many of these techniques, particularly nanomaterial and optical
techniques, rely on the use of photoactive drugs or fluorophores. This becomes challenging
for technique generalization, as few pharmaceuticals are optically active especially in the
tissue penetrating red/near infrared spectral region, and fluorophore labeling may interfere
with drug activity in vivo. MRI based techniques are advantageous for imaging through
deep tissue but are generally unsuitable for quantitative measurements, which is an
important factor when examining drug delivery. In addition, current approaches are not
capable of providing surface specific resolution in cases where drug is released from a
fixed biomedical implant.
The most common methods for infection specific imaging use radiolabeled
pharmaceuticals imaged with positron emission tomography (PET) or single-photon
emission computed tomography (SPECT), but these require expensive instrumentation and
they do not generally distinguish between drug in nearby tissue and on the implant.[10,16]
18

F-fluorodeoxyglucose positron emission tomography (FDG-PET) has been applied in the

detection of infection, as FDG accumulates in infected tissue, thereby permitting infection
specific imaging.[7,26,27] Similarly,

111

In or

99m

Tc labeled leucocyte imaging (WBC

imaging), and 99mTc-Infecton (Ciprofloxacin) have been paramount for inflammation, and
infection specific imaging.[9,28] SPECT, particularly SPECT/CT, has been used in
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conjunction with bone scintigraphy for identification of inflammatory and infectious
processes in soft tissues as well.[29,30] However, these approaches do not provide implant
surface specific information. PET radioisotope contrast agents also typically have short
half-lives, which requires close proximity to cyclotron and chemical synthesis facilities.[31]
Radioluminescence is a promising candidate for biomedical application and has
recently been used in nanoparticle-based molecular imaging and radioluminescence
imaging (RLI).[32] Cerenkov radiation luminescence has been used for luminescence
tomography, and tumor monitoring, but the phenomenon generates low light yield.
Typically, longer exposure times (3-5 minutes minimum) and higher energy radioisotopes
are required (>219 keV), and obtaining quantitative results using Cerenkov luminescence
is challenging.[33,34] Alternatively, flexible RLI has recently been done with 18F-FDG, using
a flexible terbium doped gadolinium oxysulfide film in order to improve signal to noise
ratio when imaging tumors, as compared to traditional RLI.[35] However these techniques
have similar drawbacks to PET and SPECT imaging with regard to short half-life
radioisotopes, and lack of surface specificity.
The use of scintillators to quantify radiolabeled analytes is well-documented in a
technique called scintillation proximity assay (SPA).[36] However application has typically
been confined to radioimmunoassays, enzyme assays, and ligand-receptor binding
assays.[37] We describe a method to image surface-specific drug release and/or
accumulation at the biomedical implant surface. We coated an implant with a
radioluminescent phosphor film and radiolabeled a fraction of vancomycin (a
representative antibiotic often used to treat implant infection) as a tracer to monitor release
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near the implant surface. The presence or absence of that drug at the implant surface is
indicated by the presence or absence of luminescence signal (Figure 2.1). In this study we
have used tritium labeled vancomycin (3H-vancomycin), which decays via beta-radiation,
and Gd2O2S:Eu3+ radioluminescent phosphors. The energy of an emitted beta particle
affects its range in any given medium; higher energy particles travel farther. The range can
be calculated by considering the energy of the beta-particle, and the density of the
medium.[38] In water, for example, 3H beta-particles decay with a relatively low energy (~6
keV average), and will travel a maximum of ~4 µm, with an average range closer to ~0.4
µm. If the 3H-Vancomycin can excite a phosphor film immobilized on the surface of an
implant, then the drug is within 4 µm of that implant. This permits unprecedented surface
specificity in monitoring drug release or accumulation. To translate the technique for
imaging through biological tissue, rare earth doped gadolinium oxysulfide phosphors (e.g.
Gd2O2S:Eu3+) are selected due to the high quantum efficiency (60,000 photons MeV-1 Xray in bulk gadolinium oxysulfide), distinct and narrow emission peaks, high optical
penetration depth of red emission, low toxicity, and robust photostability of the
material.[16,31] These particles emit light with narrow spectral peaks when excited by blue
light, X-Rays, or alpha/beta radiation. Gd2O2S:Eu3+ has emission peaks between 560 nm
and 750 nm due to 5D0 → 7Fj (j = 0-4) transitions of Eu3+ ions.[39] This region of visible
light is ideal for in vivo imaging because blood and tissue will absorb and scatter less light
at longer wavelengths. Using the combination of 3H-Vancomycin and Gd2O2S:Eu3+, we
can detect drug release from an implant surface with inherent micrometer resolution,
permitting unprecedented surface specificity in quantitative drug monitoring. Tritium
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labeling does not interfere with the structure or action of the labeled drug and does not rely
on photoactive properties of the drug itself. As a result, this technique may be expanded
for use with other implant types and pharmaceuticals with relative ease.

Figure 2.2. A) Fracture fixation plate coated with Hydromed D3 TM and Gd2O2S:Eu3+ microparticles. 3HVancomycin deposited with decreasing activity left to right. B) Superimposed pseudo-colored luminescence
intensity image overlayed with reflected light image taken with IVIS Lumina. Regions of luminescence
indicated with color gradient map, generated in MATLAB. Background manually removed to show regions
of interest. C) Luminescence intensity plotted against 3H-Vancomycin activity. D) Raw luminescence
intensity values (without blank or background correction) for each 30 x 30 px region in the concentration
gradient. Standard deviation values shown in both “counts” and “% of signal.”
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2.3 Results and Discussion
We developed an implant coating and imaging technique to detect drug release.
First, we demonstrated the linear dependance of luminescence signal on 3H-Vancomycin
concentration using a concentration gradient. Next, we demonstrated the ability to monitor
drug release, and examined the effect of biological tissue on the emission signal.
2.3.1 Signal vs. Concentration/Dose
As shown in Figure 2.2A-C, the luminescence spots become brighter with
increasing 3H-Vancomycin concentration. The luminescence vs. 3H-Vancomycin plot
depicts an average of 3 images captured consecutively (raw luminescence data and
standard deviation values found in Figure 2.2D). The integrated luminescence intensity in
any spot is proportional to the activity/amount of radiolabeled vancomycin deposited,
demonstrated by the highly linear correlation between photon emission and activity
deposited (R2=0.99). This is expected because the luminescence depends upon the number
of beta emissions near the phosphors, provided that all the vancomycin is deposited within
~2 µm of the phosphor surface (since the average decay range for 3H is ~0.4 µm in water
and similar density materials such as HydroMed D3TM).[40] 3H-vancomycin generates
3.7x104 decays s-1µCi-1 and, theoretically, if each decay deposits all its energy in the
microphosphors, produces 342 photons per decay (5.7 keV average decay energy for 3H *
60 photons per keV bulk Gd2O2S:Eu3+ radioluminescence quantum efficiency with X-ray
excitation), then we expect ~1.7x107 photons s-1 µCi-1 to be generated.[16,41] In our
experiment we expect fewer photons µCi-1 for five reasons: 1) not all tritium decay energy
is absorbed by the phosphors (i.e. some of the energy is deposited in the water and
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HydroMed D3TM); 2) the beta luminescence efficiency may be lower than X-ray efficiency
since energy is preferentially deposited near the microphosphor surface – which is
quenched compared to bulk[35,36]; 3) Some of the luminescence is absorbed in the phosphor
film, especially for thick samples with much internal scattering, or scattering and
absorption in tissue (if present); 4) only 5% of the 4π steradian solid angle is collected by
the objective at maximum f-number of 1; 5) There is light loss in lenses and imperfect
detector quantum efficiency.
In our experiment without tissue, we detected 5x103 photons s-1 µCi-1 (~1 photon
per 8 beta emission events), which is 0.04% of the maximum number of photons we expect
could be generated. Adding the 3H-vancomycin directly to the microphosphors (without
any HydroMed D3TM) in a white microwell plate increases the signal (Figure 2.3); at low
particle concentrations with well-washed particles the signal is 5x brighter than in the
HydroMed D3TM (0.2% of maximum theoretical number), although it decreases with
increasing particle concentration especially for unwashed particles, presumably due to
scattering and optical absorption by the microphosphors. In principle, we expect the
efficiency could be increased by 1-2 orders of magnitude using a light guide with less loss
and higher numerical aperture, and the last 1-2 orders of magnitude might be improved by
reducing surface quenching (e.g., using more deeply penetrating, higher energy betaemitters, or by embedding and annealing the emitters in the phosphors). However, even
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Figure 2.3. Radioluminescence images of white microwell plates containing 0.25 µCi 3H-vancomycin and
A) unwashed Gd2O2S:Eu3+ microphosphors; B) washed Gd2O2S:Eu3+ microphosphors. Samples are dried of
solvent, and do not contain Hydromed D3. C) The luminescence increase obtained by washing the particles
and reducing phosphor mass. This experiment is done to assess the effect of Hydromed D3, a pre-wash step,
and Gd2O2S:Eu3+ self-quenching, on β- excitation and particle emission efficiency.

with its inefficiencies, the current system provides a clear linear increase in luminescence
with 3H-vancomycin concentration using relatively low activity.
Based on standard deviation of the blank intensity (sb), and the slope of the linear
regression line from the concentration gradient (m) we find a concentration LOD (3*sb/m
= 9.6 nCi = 0.35 pmol vancomycin) and a limit of quantification (10*sb/m = 32 nCi or 1.2
pmol vancomycin). This is sufficient for the application: the minimum vancomycin
inhibitory dose (MIC) is 1.5 mg L-1 [42], and typical drug loading concentrations, intended
for localized release over time, are on the milligram scale. [43,44] Since picomoles of 3Hvancomycin can be measured with this technique, 3H-vancomycin can be added as a tracer
to therapeutic, un-labeled vancomycin to track release. These images are acquired using a
2 min exposure time, but longer exposure time would increase the signal-to-noise ratio,
thereby improving sensitivity. In practice, exposure time is likely limited to ~30 minutes
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or eventual applications in animal or human subjects due to need for keeping subject still
and issues relating to cosmic spike removal.
2.3.2 Monitoring Drug Release
To demonstrate that the technique can be used to track drug release, we measure
luminescence as the plate, coated with unlabeled Vancomycin and 3H-Vancomycin as a
tracer, is periodically submerged in DI water. Unlabeled Vancomycin is spiked with 3HVancomycin to monitor biologically relevant concentrations of drug while keeping the
radioactivity as low as reasonably achievable for the technique. Specifically, in the signal
vs. concentration experiment, only 3H-Vancomycin is used with an activity of 1.9x104
µCi/mg (i.e. we used ~53 ng total 3H-Vancomycin at the highest activity). For the
subsequent drug release study, the 3H-Vancomycin is mixed with unlabeled Vancomycin
in a mass ratio of 1:5000 (i.e., we used ~210 ng of tritium labeled vancomycin and 1 mg
of unlabeled vancomycin). A recent study found that a mixture of 0.1 mg vancomycin and
0.2 mg of chitosan plasma deposited on a tibial plate prevented infection in a staph aureus
challenge rabbit study.[45] The blank and constant drug reference region are encapsulated
in PDMS to prevent any changes in drug concentration at the surface to have a constant
region for comparison through tissue section. As drug is dissolved by the water and
released from the drug release region, the luminescence intensity goes down proportionally
while the blank and constant drug reference regions maintain constant luminescence
intensity (Figure 2.4A). The luminescence vs. Vancomycin released plots depict an
average of 3 images captured consecutively for 0 mm tissue, and 1 image captured
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Figure 2.4. A) Fracture fixation plate coated with HydroMed D3TM in three regions. Drug release region and
constant drug reference region contain 3H-Vancomycin. Blank and constant region are encapsulated using
PDMS. Images demonstrate luminescence decrease in drug release region as drug elutes from surface.
Images captured using IVIS Lumina, with color map representing luminescence intensity B, C, and D)
Luminescence regions of interest are imaged through 0 mm, 5 mm, and 10 mm of porcine tissue. Vertical
line through each indicates the line used for the intensity profile in E. E) Intensity profile plotting signal
intensity vs. location for vertical line through each image.

for 5 mm tissue (raw luminescence data and standard deviation values for 0 mm tissue
experiment can be found in Figure 2.6C).
The plate is imaged through 0 mm, 5 mm, and 10 mm of porcine tissue (Figure 2.4
B, C, D). Light scattering in the tissue causes the image to blur so that features are poorly
resolved. Previous studies have shown that the point spread function is about 20 mm for
650-800 nm light through 10 mm of tissue (in slab geometry).[46] The intensity profile of
vertical lines through the center of each image demonstrates the signal decrease and spread
for the drug release region (left-most peak) and constant drug reference region (right-most
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peak) (Figure 2.4E). The full-width half-max (FWHM) for the signal through 5 mm, and
10 mm of tissue, calculated after four iterations of gaussian smoothing (Figure 2.5A-B) to
reduce image noise, is 13.1 mm, and 16.5 mm, respectively. If the reference region is
separated by >16.5 mm, it can be resolved from the drug eluting region through 10 mm
tissue. If they are closer, the reference may need to be distinguished from the sensor region,
e.g., using spectrally distinct scintillators.

Figure 2.5. Intensity profile of a vertical line drawn through the center of the implant, from images taken
through 0, 5, and 10 mm of porcine tissue. The left-most peak represents the drug release region and the
right-most peak represents the constant drug reference region. A) The plot before gaussian smoothing.
FWHM of left-most peak for 0 mm tissue is 3.36 mm. B) The plot after four iterations of gaussian smoothing.
FWHM of left-most peak for 0 mm tissue is 3.66 mm. C) Luminescence signal attenuation factor vs tissue
thickness. The luminescence signal is attenuated exponentially with tissue thickness. Signal decreases by an
attenuation factor of ~7.6 through 5 mm tissue, and a factor of 30 through 10 mm of tissue. The exponential
fit is useful for determining how much the luminescence signal is expected to decrease through larger tissue
depths.
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In addition to reduced spatial resolution, the total signal intensity decreases when
imaged through tissue due to a combination of absorption and scattering. The integrated
signal decreases by a factor of ~7.6 through 5 mm of tissue, and a factor of ~30 through 10
mm of tissue in the range of reported effective attenuation coefficients.[47] The attenuation
coefficient increases exponentially with tissue thickness, as shown in Figure 2.5C. Despite
tissue signal scattering and absorption, the drug release region and constant drug reference
luminescence can be resolved due to the spatial separation of the regions (Figure 2.4C, D).
Since the tissue thickness is roughly constant over the region imaged, the ratio between
drug release and reference regions accounts for common mode attenuation in the tissue.
After an initial equilibration period, as HydroMed D3™ absorbs water, the drug release
profile is highly linear, with R2 values of 0.99 without tissue, and 0.98 with 5 mm of porcine
tissue (Figure 2.6). Despite equal amounts of 3H-vancomycin being deposited, the constant
drug reference exhibits lower luminescence intensity compared to the initial drug release
region intensity. This is due to the PDMS layer deposited on the blank and constant drug
reference. The deposited PDMS interferes with the 3H-vancomycin coating, likely placing
>2 µm distance between the phosphor film and some of the 3H-vancomycin molecules,
thereby inhibiting efficient excitation. Nonetheless, the signal remains constant after
coating (HydroMed D3TM) equilibration.
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Figure 2.6. A) Luminescence vs 3H-Vancomycin without tissue. Left graph shows constant drug reference
and drug release region. Right graph shows the ratio of the linear region of drug release/constant drug
reference, after Hydromed D3 equilibration. B) Same as A) except images acquired through 5 mm porcine
tissue. C) Raw luminescence intensity values of the 30 x 30 px drug release region (without blank or
background correction) for each drug release point. Standard deviation values shown in both “counts” and “%
of signal.”
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The blank region between the drug release and constant drug reference could not
be resolved through tissue due to scattering. This can be remedied by coating the blank
region a sufficient distance away from the drug release and constant reference regions
(>13.1 mm for 5 mm porcine tissue). The blank region is useful for background subtraction
because Gd2O2S:Eu3+ generates a background from long-lived afterglow following earlier
exposure to room light, even in the absence of 3H-vancomycin. Consequently, a blank
region must be subtracted to account for background luminescence not caused by 3Hbetaluminescence (this especially affects measurements with low concentrations of 3Hvancomycin). Because the blank region could not be resolved through tissue, the blank is
estimated using the value of the blank without tissue adjusted using the attenuation factor
determined from the constant drug reference. Additionally, in Figure 2.7 we show a
correction that can be done to account for light emission crosstalk between the drug release
and constant drug reference when imaged through tissue. Crosstalk is estimated to be ~5%,
although deconvolution of the intensity profile (Figure 2.4E) would be required to
determine the exact value. The effect is minimal but permits correction of the artificially
high signal of the drug release plot through 5 mm tissue relative to the same plot with 0
mm tissue. Nonetheless, using only a 4 µCi spike of 3H-vancomycin in an otherwise
unlabeled sample of vancomycin, we find a LOD of 38.6 nmol (56 µg) vancomycin through
5 mm of tissue. For tissue depths >10 mm, exponential attenuation of luminescence signal
with tissue thickness presents a challenge with signal intensity decreasing by a factor of 30
per centimeter (Figure 2.5C). However, the decreased signal can be compensated for by
increasing exposure time past 60 s, improving optical collection efficiency, and/or using a
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Figure 2.7. A) Drug release intensity ratio plots through 0 mm and 5 mm porcine tissue, A) before
crosstalk correction, and B) with an additional correction for 5% signal crosstalk. When imaged through
tissue, some of the signal from the drug release region bleeds in to the constant drug reference region due
to scattering (and vice versa). This causes the drug release plot to have an artifically higher signal than the
plot without tissue.

higher 3H-vancomycin activity. Additionally, the effective tissue thickness can be
decreased by mechanical indentation to the region of interest when imaging.[48]

2.3.3 Radiation Dose Concerns
Our technique could have medical or pre-clinical applications. Medical procedures
should use doses as low as feasible but must balance the potential risks from extra radiation
(especially long-term potential for oncogenesis) against immediate medical needs. Risks
depend on many factors, including patient age, radioisotope chemical form, route of entry,
and clearance half-life. The most commonly employed linear no-threshold model suggests
that incidence of deadly cancers increases by 5.5% per 1 Sievert (Sv) effective full-body
radiation dose (1 Sv represents the equivalent biological effect of 1 Gray (Gy), or 1 joule
kg-1).[49] For routine imaging studies, effective doses are typically between 0.1-20 mSv. As
a contrast, when tissue ablation is desired (e.g. in high dose rate brachytherapy and to treat
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ectopic bone) doses are typically >12 Gray (Gy).[50] Nuclear medicine techniques to image
bone healing and infection diagnostics typically use

18

F PET and

99m

Tc SPECT

administered intravenously at dosages between 5-10 mCi, and 20-30 mCi,
respectively.[51,52] Although tritium is not used in imaging studies because the beta emission
is not energetic enough to penetrate through the tissue (except if a nearby scintillator
converts the energy to light), the ICRP estimates that a 20 mSv effective full body dose
would require 30 mCi for tritiated water, 24 mCi for 99mTc, and 11 mCi for 18F.[53]. Tritium
labeled pharmacokinetic studies in patients typically use 200 µCi doses.[54]
Less than 1 µCi of 3H-vancomycin is used in the signal vs. concentration/dose
experiment, and the drug release portion of our study uses a maximum of 8 µCi 3HVancomycin. We note that tritium has a much longer radioactive half-life than most
imaging radionuclides such as

99m

Tc and

18

F (12.3 years, 6 hours, and 1.8 hours,

respectively).[40,55,56] Dose is thus limited by biological clearance rather than physical halflife. The ICRP estimate is based upon a 10-day circulation half-life for tritiated water. The
vancomycin has an even shorter circulation half-life (6 hours).[57] Although the implant
increases the amount of time the radioactive drug is in the body (with release programmed
over days or weeks), while drug is in the implant coating it primarily irradiates the polymer
coating rather than the tissue. Specifically, radiation exposure is localized to tissues at the
interface within ~0.4 µm of the coating surface (average beta decay range average 5.7 keV
3

H beta particle in tissue), although a smaller fraction of energy is deposited within 5 µm

from the surface (maximum 18.6 keV beta emission when normal to the surface).[58] For a
drug-eluting coating several hundred micrometers thick which releases drug over days or
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weeks, the radiation dose to the tissue from the interface is small compared to the dose
from released drug. For the constant drug region, which is encapsulated with several
hundred µm of PDMS, only the polymer experiences radiation, not the tissue. Although
leakage of 3H-Vancomycin from the encapsulated region is not expected to occur, any
leakage will be cleared from the body at the same rate as the 3H-Vancomycin released from
the drug release region.
As a final reference point, the EPA declares a Maximum Contaminant Level (MCL)
of 14 µCi per year (assuming an intake of 2 L water per day at 20,000 pCi/L tritium activity)
for beta radiation in drinking water.[59] Although these dose limits specifically do not apply
to medical exposures which can be much higher, the dose we employed in our experiment
is below this level too. In summary, radiation used should be as low as feasible, and the
radiation used in these experiments was quite low by most medical standards.

2.4 Methods
2.4.1 Fracture Fixation Plate Preparation
A 9-hole, 3.5 mm Small Fragment Locking Compression Plate (LCP™ part number
223.591, DePuy Synthes USA Products, LLC, West Chester, PA, USA) is coated with
Gd2O2S:Eu3+ microphoshor particles (8 µm median diameter, part number UKL63/N-R1,
Phosphor Technology LTD, Stevenage, UK) using HydroMed™ D3 polyurethane
(AdvanSource Biomaterials Corp, Wilmington, MA, USA). The HydroMed™ D3 and
Gd2O2S:Eu3+ microphoshor particles are combined in a 1:30 ratio, in dichloromethane.
Characterization of the phosphor particles is performed by Phosphor Technologies using a
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Coulter Counter with 100 µm aperture: 95 volume % below 13.2 µm diameter (Figure
2.8B). The LCP™ is coated with the mixture via drop wise deposition and solvent
evaporation. 3 layers are deposited to ensure uniform coating. Figure 2.8A depicts an
example of one layer, imaged using Nikon Eclipse TE2000-U microscope (Nikon

Figure 2.8. A) Microscope images of Gd2O2S:Eu3+ microphosphors in a thin layer of Hydromed TM spread
over a glass slide (a thin region at the edge was selected so that the particles could be distinguished). Three
layers are deposited onto the LCPTM to ensure uniformity. Primary image shows brightfield light transmission
image taken at 4X plus 1.5X magnification (scale bar 150 µm). Inset image is taken at 40X plus 1.5X
magnification, with UV excitation to demonstrate luminescence and packing. B) Gd 2O2S:Eu3+
microphosphor characterization performed by Phosphor Technologies LTD.
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Instruments Inc, Melville, NY, USA). The HydroMed™ D3 permits immobilization of the
microparticles on LCP™ surface.
2.4.2 Vancomycin Deposition – Signal vs. Concentration/Dose
3

H-Vancomycin (27.5 Ci mmol-1, ViTrax Radiochemicals, Placentia, CA) is

prepared via serial dilution using deionized water and deposited in 8 spots on Gd2O2S:Eu3+
coated LCP™. The deposited 3H-Vancomycin spots contain 0.5, 0.25, 0.12, 0.06, 0.03,
0.015, 0.008, and 0.004 µCi 3H (26.8, 13.4, 6.7, 3.4, 1.7, 0.8, 0.4, and 0.2 ng Vancomycin).
Following 3H-vancomycin deposition, LCP™ is dried at room temperature (~23°C), to
evaporate any remaining solvent.

2.4.3 Vancomycin Deposition – Drug Release
This technique involves the use of three regions, one drug release region, one blank
region, and one constant drug reference region. The drug release and constant drug
reference regions must be sufficiently separated to visually distinguish after emission
signal blurring and point spread as it passes through tissue. The fracture fixation plate is
prepared using the drop coating and solvent evaporation method of 1:30 HydroMed™ D3
and Gd2O2S:Eu3+ microphoshor particles in dichloromethane. An X-Acto Precision Knife
is used to cut the uniform coating into three distinct regions (the drug release region, blank
region, and constant drug reference region) before Vancomycin deposition. To slow drug
release, the deposited vancomycin mixture is prepared with 10 mg mL-1 unlabeled
Vancomycin, 0.04 mCi mL-1 3H-vancomycin, and 5 mg mL-1 chitosan, in 1 M acetic acid.
100 µL of mixture (4 µCi 3H) is deposited on the drug release region and constant drug
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reference regions. The constant drug reference region is sealed using polydimethylsiloxane
(PDMS), in order to prevent drug elution and produce a consistent emission signal.

2.4.4 Image Acquisition
Radioluminescence images are acquired on a small animal imager (IVIS Lumina
XR, Perkin Elmer, Waltham, MA) under luminescence photograph mode (no external light
source). For signal vs. concentration experiment, 3 images are acquired consecutively with
120 s exposure time, medium binning, field of view “C”, and an aperture f-stop of 1. The
experiment is performed 1 time. For drug release experiment, 3 images are acquired
consecutively with 20 s exposure time (0 mm tissue), and 1 image is acquired with 60 s
exposure time (5- and 10-mm tissue) at each drug release point. The experiment is
performed 1 time. For limit of detection and limit of quantification, the LCP™ is imaged
consecutively 10 times with an exposure time of 120 s each (0 mm tissue). Other settings:
medium binning, field of view “C”, and f-stop of 1. The sample holder is manufactured
using a 3D printer (MAKEiT, Inc, Alhambra, CA, USA) and white, acrylonitrile butadiene
styrene (ABS) filament. The sample holder is attached to the IVIS stage using double-sided
tape to ensure consistent placement of the implant in the imaging chamber. Raw
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luminescence images are collected and analyzed via custom MATLAB scripts [appendices
A-C].

2.4.5 Tissue Preparation
Porcine tissue (pork, center cut loin chops, boneless) is acquired from the
supermarket (Walmart Neighborhood Market, Clemson, SC, USA) and sliced into sections
of controlled thickness using a Gourmet Electric Food Slicer (Model 630, Chef’s Choice
International, Avondale, PA, USA). These sections are placed over the plate to observe the
effect of increasing tissue thickness on the signal. 5 mm and 10 mm sections are used for
the drug release experiment.

2.4.6 Image Analysis
Raw luminescence images are analyzed using custom MATLAB scripts. For
concentration vs. signal experiment, 8 regions are analyzed for the concentration gradient
(0.5, 0.25, 0.12, 0.06, 0.03, 0.015, 0.008, and 0.004 µCi 3H-vancomycin), and 1 blank
region, containing HydroMed™ D3 and Gd2O2S:Eu3+ microphoshor particles, is analyzed
to correct for background and phosphor afterglow. Each region is 30 x 30 px (Figure 2.9),
and the coordinates are kept consistent for each image. The blank region counts are
subtracted from each concentration gradient region to obtain luminescence signal
contributed by 3H-vancomycin.
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Figure 2.9. A) Reflected light and radioluminescence image of LCPTM plate coated with Gd2O2S:Eu3+
microphosphors, and HydroMedTM D3. From top to bottom, the first and third region also contain 3Hvancomycin. Five blank regions are used to determine the standard deviation of the blank for LOD
calculations. B) Example 30x30 pixel region generated from IVIS luminescence image, analyzed for LOD
and LOQ determination.

For the drug release experiment, 4 regions of interest are analyzed for each photo:
Drug Release, Blank, Constant Drug Reference, and Background. Each region is 30 x 30
px, and the coordinates are kept consistent for each image. The sum-total counts are
obtained for each region and exported to excel. The blank region counts are subtracted
from the drug release and constant drug reference signals to obtain the luminescence signal
for each drug release point (this is also done for signal vs. concentration images). Each
drug release point is imaged 3 times, and the luminescence value for the drug release and
constant drug reference regions are averaged. There are 13 drug release points, each imaged
3 times, for an analysis of 39 photos. For the images acquired through tissue, a similar
analysis is performed using the same 30 x 30 px regions described above.
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Since light emitted from the drug release and constant drug reference regions both
scatter into the blank region between them, the blank is difficult to calculate directly. In
principle, we could use regions where there are no nanophosphors, but such blanks would
not account for the significant afterglow signal we observe after exposing the plate to an
overhead light during the imaging and drug elution procedure. This afterglow artifact varies
between 2% and 7% of the constant drug reference region and would be both dramatically
lower and more predictable in a live system after implantation, not periodically opened and
exposed to light (especially blue and ultraviolet excitation). We corrected for the artifact
by measuring the intensity for the blank without tissue and adjusting using the tissue
attenuation factor (A) determined from the change in signal intensity in the constant drug
reference region without tissue and with 5 mm tissue. A is calculated by first subtracting
the background (a 30 x 30 px region next to the plate without phosphors) from the 30 x 30
px constant drug reference region for the data sets without tissue and with 5 mm tissue.
Specifically, the constant drug reference region with 0 mm tissue (Ct0) is corrected using a
background region from the image taken with 0 mm tissue (BGt0), and the constant drug
reference with 5 mm tissue (Ct5) is corrected using a background region from the image
taken with 5 mm tissue (BGt5). The ratio of the background corrected constant drug
reference with 0 mm tissue (Ct0 - BGt0) to the background corrected constant drug reference
with 5 mm tissue (Ct5 - BGt5) is calculated for each drug release point, using Equation (1),
to determine A. The blank values (Bt0) obtained from the images without tissue are then
divided by A to estimate the blank values through 5 mm tissue (Bt5) using Equation (2).

52

𝐶 −𝐵𝐺

(1)

𝐴 = 𝐶𝑡0−𝐵𝐺𝑡0
𝑡5

𝐵𝑡5 =

𝑡5

𝐵𝑡0

(2)

𝐴

These blank values and background values are then subtracted from the drug release
(DRi5) and constant drug reference (Ci5) values obtained through 5 mm tissue to estimate
and correct for luminescence from afterglow. Equation (3) and (4) yield the final corrected
drug release (DRf5) and constant drug reference (Cf5) regions through 5 mm tissue.

𝐷𝑅𝑓5 = 𝐷𝑅𝑖5 – 𝐵𝐺𝑡5 – 𝐵𝑡5

(3)

𝐶𝑓5 = 𝐶𝑖5 – 𝐵𝐺𝑡5 − 𝐵𝑡5

(4)

To correct for the 5% crosstalk observed between radioluminescence at the drug
release and constant reference region (based upon the intensity profile), we multiply the
observed values by the inverse matrix giving a final crosstalk corrected drug release value
(DRf) and constant drug reference value (Cf) (equations 5 and 6). This correction is shown
in Figure 2.7 and had a small but measurable effect on the calibration.

1

𝐶𝑟𝑜𝑠𝑠𝑡𝑎𝑙𝑘 𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 𝐷𝑅𝑓 = (1−0.052 )(𝐷𝑅𝑓 – (0.05 ∗ 𝐶𝑓 ))
1

𝐶𝑟𝑜𝑠𝑠𝑡𝑎𝑙𝑘 𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 𝐶𝑓 = (1−0.052)(𝐶𝑓 – (0.05 ∗ 𝐷𝑅𝑓 ))
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(5)
(6)

To calculate LOD and LOQ, the LCP™ is coated with an additional 4 blank regions,
for a total of 5 blank regions (Figure 2.9). The plate is imaged 10 times, with an exposure
of 120 s each. The blank regions (30 x 30 pixels) in each image are analyzed in MATLAB
and exported to excel, as described above. To determine variation in the blank, the
luminescence counts from blank region 1 are subtracted from each of the additional blank
regions. The standard deviation of these values (Sb) is used along with the slope of the
regression line (m), taken as an average of 3 analyzed images of the concentration gradient,
each with a 120 s exposure and no tissue, to calculate LOD and LOQ in Equation (7) and
(8).

𝑆

(7)

𝐿𝑂𝐷 = 3 ∗ ( 𝑚𝑏 )
𝑆

(8)

𝐿𝑂𝑄 = 10 ∗ ( 𝑚𝑏 )

To evaluate effect of tissue on signal spread and attenuation, an average of the
intensity profile of three vertical lines through the center of 0 mm, 5 mm, and 10 mm
images, prior to submersion in water for drug release, are co-plotted. The full width half
maximum (FWHM) from these intensity profiles is used to estimate signal spread through
5 mm and 10 mm tissue. The maximum signal intensity value from the 0 mm tissue image
is divided by the maxima from 5 mm and 10 mm tissue images to estimate attenuation
factors.
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2.4.7 Liquid Scintillation Counting
To verify the amount of 3H-Vancomycin eluted during drug release, each drug
release image is taken after dipping the plate into 10 mL of DI water. Each 10 mL sample
of water is analyzed by drawing a 100 µL aliquot and adding it to 15 mL of Ultima Gold
uLLT liquid scintillation cocktail (Perkin Elmer, Waltham, MA). The samples are counted
three times each, for one minute, using a liquid scintillation counter (Beckman Coulter LS
6500, Brea, CA), yielding the count rate of sample before addition of internal standard (Cs).
Internal standard of known disintegration rate (Di) and concentration (10 µL of 5 µCi mL1

) is then added to each vial and counted again for one minute, three times each, yielding

the count rate after addition of internal standard (Cs+i). The samples are shaken, then light
adapted for 30 minutes before counting. The counting efficiency (E) is first calculated
using Equation (9). The activity of 3H-Vancomycin (Ds) is then extrapolated from the
values of E and Cs, using Equation (10).[38]

𝐸=

(𝐶𝑠+𝑖 + 𝐶𝑠 )

𝐷𝑠 =

(9)

𝐷𝑖
𝐶𝑠

(10)

𝐸

2.4.8 Evaluation of Gd2O2S:Eu3+ Amount and Wash Step
Gd2O2S:Eu3+ microphoshor particles (8 µm median diameter, part number
UKL63/N-R1, Phosphor Technology LTD, Stevenage, UK) are washed 3x in DI water,
and 1x in ethanol. Washing is done by immersing 2 g of phosphor particles in 50 mL of
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solvent, agitating, centrifuging at 10,000 rcf, and discarding supernatant. After washing,
particles are placed in the oven to dry at 90°C for 1 hour. Unwashed particles are used
directly from original packaging, with no prior treatment step. 2 Optiplate-96, opaque white
96-well microplates (Perkin Elmer, Waltham, MA) are used. For unwashed particle plate,
20 mg Gd2O2S:Eu3+ is placed into wells D2, D4, and D6, 50 mg is placed into wells F2,
F4, and F6, and 100 mg is placed into wells H2, H4, and H6. For washed particle plate, 25
mg Gd2O2S:Eu3+ is placed into wells D2, D4, and D6, 50 mg is placed into wells F2, F4,
and F6, and 100 mg is placed into wells H2, H4, and H6. 0.25 µCi 3H-vancomycin is also
deposited into each well, with excess solvent evaporated in the oven at 50°C for 1 hour.
Radioluminescence images (Figure 2.3) are acquired on a small animal imager (IVIS
Lumina XR, Perkin Elmer, Waltham, MA) under luminescence photograph mode (no
external light source).

2.5 Conclusion
We demonstrate a method to visualize and quantify 3H-vancomycin escaping from
the surface of a biomedical implant using a CCD camera (IVIS Lumina). Our work
demonstrates this technique applied in detecting trace concentrations of radiolabeled
antibiotics on the surface of an orthopedic implant. Orthopedic implants are susceptible to
colonization by bacterial biofilms, which often require aggressive, and invasive treatment
for eradication. Antibiotic eluting implant coatings are a promising candidate for both
prevention and treatment. The present method permits surface specific evaluation of drug
concentration on biomedical implants, which is an important metric for development of
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effective drug release coatings. 3H labeling is not expected to interfere with drug molecule
activity, which makes this an attractive approach for concentration measurements of other
analytes near the implant surface using simple cameras.
LOD and LOQ calculations were performed based on the results of each
experiment, where noise was acquired from the same sample measured sequentially, and
slope was determined with respect to the difference between the blank and constant
reference. The values do not reflect reproducibility between separate experiments using
different implants and different days or instruments, which would be expected to show less
reproducibility especially with respect to the background. Nonetheless, they do provide an
indication of a minimum under the conditions used. LOD and LOQ calculations are
performed based on standard deviation of the blank intensity (sb), and the slope of the linear
regression line from the concentration gradient or drug release gradient (m), respectively.
The standard deviation of the blank (sb) was based on 10 images of 5 blank regions (each
with only Gd2O2S:Eu3+ and HydroMedTM D3), acquired consecutively. The standard
deviation in the blank regions was found to be 1729 average counts. Error bars are not
reported in the signal vs. concentration linear regression plot (Figure 2.2C) or drug release
linear regression plots (Figure 2.6 A/B) because the standard deviation of these
measurements was less than 0.1% and 0.35% of the total luminescence signal, respectively
(Figure 2.2D and 2.6C). The standard deviation of these measurements was determined
from the variation in three separate images of the same film, acquired consecutively.
The primary sources of noise for a CCD imaging system are dark noise, read noise
and shot noise. Dark noise is calculated to be 0.2 e-/pixel based on the dark current
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(Id<3x10-4e-/pixel/s) of the CCD camera and the integration time (ti=120 s for the signal
vs. concentration experiment) using equation 11.
(11)

𝐷𝑎𝑟𝑘 𝑁𝑜𝑖𝑠𝑒 = √𝐼𝑑 × 𝑡𝑖

Read noise for the CCD camera is reported to be better than 5 electrons. The shot
noise is proportional to the square root of the average number of events. For example, if
we examine the average of 3 images in the 0.5 µCi region for the signal vs. concentration
experiment, N=268,560 photons. Theoretical shot noise, then, is 518 photons. The
experimental standard deviation in the signal for this region, amongst the three images, is
845 photons. This trend is seen throughout the data, so the signal appears to be shot noise
dominant at reasonably high signal intensities. At low analyte concentrations, a major
source of noise is variation in long lived phosphorescence afterglow after exposure to
visible light. This can be decreased by preventing blue and UV light exposure for hours or
days prior to luminescence imaging, as would likely be the case in a real implant
experiment.
As this method is repeated, and individual experiments are compared, we expect
the standard deviation to increase and the LOD/LOQ to increase accordingly. However, as
previously described, we can increase the concentration of radiolabel and increase
exposure time to improve signal to noise ratio and sensitivity; improving the optical
collection efficiency and scintillator betaluminescence efficiency would also help.
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CHAPTER 3
MONITORING 3H-VANCOMYCIN CONCENTRATION USING
RADIOLUMINESCENT NANOPARTICLES
3.1 Abstract
Nanoparticles are a useful biomedical tool for imaging and targeted drug release,
but drug release pharmacokinetics are generally investigated and characterized in vitro.
Due to patient heterogeneity, and variable drug release behavior in different biological
tissue environments, there remains a need for quantitative in vivo tracking strategies. In
this chapter we provide proof of concept for using radioluminescent nanophosphors to
measure radiolabeled drug release in vivo. We present a functionalization strategy for
synthesized Gd2O2S:Eu3+ nanoparticles with anti-vancomycin IgM antibodies, which
permits binding of tritium labeled vancomycin (3H-vancomycin). Successful binding of
3

H-vancomycin to radioluminescent Gd2O2S:Eu3+ nanoparticles in aqueous suspension is

expected to produce a luminescent signal that would not be present if unbound. Initial
experiments demonstrate a linear relationship between nanoparticle luminescence emission
and concentration of vancomycin (LOD=7.8 nCi) using only 1 mg dry nanoparticles.
Gd2O2S:Eu3+ emits red light with high quantum efficiency, which has been demonstrated
to penetrate biological tissues sufficiently for quantitative imaging applications.[1–5]
Monitoring decrease in luminescence emission intensity as a function of radiolabeled drug
release from nanoparticles is a conceptually simple, promising avenue for development of
a novel theranostic imaging strategy.
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3.2 Introduction
Nanoparticles, most commonly defined as being 10-100 nm in diameter[6], are
heavily investigated for imaging and therapeutic biomedical application. The 10-100 nm
size range is appealing because particles are large enough to avoid renal clearance, but
small enough to avoid rapid clearance by the reticuloendothelial system (RES).[7] This
permits a long blood circulation time which gives the particles more time to bind specific
targets. Additional factors that affect particle circulation and clearance include surface
charge, functional groups, protein corona, morphology, and mechanical properties. In
addition, nanomaterials in this size range have a large surface-to-volume ratio, which
provides high surface area for drug loading (in cases where drug is surface loaded). Besides
high surface area, nanoparticle drug carriers are often able to impart selective and targeted
release pharmacokinetics.[1] This is useful when drug is needed in a specific location and
may increase drug potency with a lower overall dose. Depending on the material used,
nanoparticles also have potential for use in combinatory imaging and therapy.[3,8]
The list of nanomaterials for drug delivery application is extensive and includes a
variety of different nanomaterials, pharmaceutical drugs, and biological targets. For
example, cancer is a popular target for nanotherapeutics because traditional chemotherapy
wreaks havoc on the body due to non-specific targeting that results in severe side effects
and ineffective treatment. Biomimetic nanoparticles[9,10], nanogels[11,12], and inorganic
nanoparticles[13,14] have been investigated for cancer immunotherapy.[15] Many types of
metal, and metal oxide nanoparticles have been used to add imaging capability to drug
delivery. For example, “smart” europium doped gadolinium oxysulfide (Gd2O2S:Eu3+)
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nanocapsules

have

been

developed

to

release

photoactive

doxorubicin

(a

chemotherapeutic) at pH values found in tumor tissue.[1] Gd2O2S:Eu3+ is radioluminescent
and paramagnetic, so these nanocapsules can be monitored both optically (as doxorubicin
release affects the emission spectrum of Gd2O2S:Eu3+) and by MRI.[3]
Despite the exponential increase in nanomaterials for biomedical application, there
is still a lack of systematic methodology to evaluate drug release pharmacokinetics and
pharmacodynamics in vivo. For materials with appropriate magnetic properties and
electron density, magnetic resonance imaging (MRI) and computed tomography (CT) are
useful for imaging nanoparticle localization through deep tissue, but are generally unable
to provide quantitative information about drug release.[16] A variety of in vitro techniques
are used to study fundamental information about drug release and behavior in biological
conditions and are usually relied upon to predict in vivo behavior.[7] These methods include,
but are not limited to, sample and separate (SS), dialysis, and continuous flow (CF). While
in vitro evaluation of pharmacokinetics is useful, treatment efficacy also depends largely
on factors that must be evaluated in vivo. There is significant variation among patients,
which includes disease progression, drug biodistribution, and drug release kinetics in
different tissue environments. Multimodal theranostic nanomaterials, which combine
therapeutic and diagnostic modalities in the treatment of disease, are lucrative for
evaluating drug release and therapeutic efficacy in real time.[4,17] Gd2O2S nanoparticles are
a promising candidate for multimodal imaging application due to low toxicity, MRI
contrast, and luminescence properties.[16,18,19]
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Gd2O2S:Eu3+ radioluminescent phosphors exhibit high quantum efficiency (60,000
photons per MeV X-Ray in bulk phase) with narrow, highly penetrating red emission.[19]
Specifically, emission peaks are located in the region between 560-750 nm (due to 5D0
→7Fj , where j=1-4, electronic transitions). For in vivo optical applications, using light in
the visible wavelength range, red light emission is ideal because penetration depth in tissue
increases as wavelength increases.[20] Luminescence emission can be stimulated by X-Ray,
UV, and radioactive decay such as beta-radiation. As a result, by radiolabeling an analyte
of interest, Gd2O2S:Eu3+ can be used to measure analyte concentration as a function of
luminescence intensity.[2] In addition to appealing optical properties, various toxicological
studies demonstrate that gadolinium based contrast agents are safe at clinically indicated
doses (except in patients with advanced renal insufficiency).[21,22] More specifically,
according to a comprehensive biodistribution, elimination, and toxicological study,
Gd2O2S nanoparticles are well tolerated, with the majority of injected product eliminated
through the feces within five months.[23]
Tritium (3H) is an appealing radiolabel because it should not interfere with the
pharmaceutical action of a drug, and the associated energy of decay (~5.7 keV) is sufficient
to stimulate significant luminescence emission in

Gd2O2S:Eu3+, but low enough to

minimize stochastic effects in vivo (see 2.3.3 “Radiation Dose Concerns”). In addition, the
decay range of 3H (0.4-4 µm in water) means excitation of phosphors in an aqueous
suspension will only occur if the 3H-analyte is attached to the phosphor (or closely
associated). This concept is well-documented for quantification of radiolabeled analytes in
scintillation proximity assays (SPA). This assay methodology typically requires plastic
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(polyvinyl toluene and polystyrene with diphenyl anthracene) or inorganic (cerium doped
yttrium silicate and yttrium oxide) scintillator beads, scintillation cocktail, and a liquid
scintillation counter.[24,25] Application of SPA has been confined to radioimmunoassays,
ligand-receptor binding assays, and enzyme assays. Monitoring drug release using
phosphorescent Gd2O2S:Eu3+ is a novel application. The previous chapter describes
measuring radiolabeled drug concentration on the surface of a locking compression plate
using 8 µm commercially synthesized particles in an immobilized film (Chapter 2). This
chapter aims to demonstrate the feasibility of measuring drug concentration on in-house
synthesized and functionalized nanoparticles in an aqueous suspension. Specifically, we
investigate the ability of 3H-vancomycin, a representative antibiotic in the treatment of
implant associated infection, to excite Gd2O2O:Eu3+ nanoparticles.[26] This technique is a
promising step toward monitoring nanoparticle drug release, quantitatively, in vivo.

3.3 Nanoparticle Synthesis and Characterization
3.3.1 Gd2O2S:Eu3+ Nanoparticle Synthesis
There are a variety of synthetic strategies to produce rare earth based luminescent
nanomaterials, and the selected method depends largely on desired size range. Uniform
crystal lattice structure, and high luminescence efficiency are ubiquitously desired, but
intended application determines the target size range. Solid-state synthetic flux routes are
used to generate larger particles (2.5-25 µm diameter), for application in biomedical XRay scintillator screens or TV cathode-ray screens.[19,27,28] For example, Gd2O2S:Tb3+ can
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be synthesized from Gd2O3 commercial precursor via an alkaline polysulfide formed in
situ using an alkaline-carbonate flux. Luminescent activator Tb3+ ions are incorporated into
the host lattice during this process as well.[29] However, traditional solid-state flux methods
have not been shown to produce particles on the nanoscale. The most common solution
based synthetic routes for lanthanide nanomaterials are thermal decomposition[30,31],
solvothermal[32,33], and coprecipitation in either aqueous or organic solution.[34]
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Figure 3.1. A) Synthesis schematic for Gd2O2S:Eu3+ nanoparticles. B) TEM image of synthesized particles.
Image taken at 100,000x magnification. C) Size analysis of 18 TEM images, and 1565 individual particles.
Number of particles is plotted vs. bins according to diameter in nm. D) Powder XRD of synthesized particles
(top) plotted in comparison to GOS standard (bottom). E) X-Ray excited optical luminescence spectrum of
synthesized particles compared to commercial microparticles.

70

Coprecipitation of gadolinium and europium nitrate salts, in aqueous solution under
decomposition of urea, is a simple synthetic strategy that can yield monodisperse particles
with high luminescence intensity.[19] Urea decomposes into ammonium and carbonate ions
in aqueous media. Basicity imparted by ammonia helps trigger initial spontaneous
nucleation, which then reduces the precursor (carbonate) concentration below the
nucleation threshold as the particles grow. The continued slow production of carbonate
precursor from urea decomposition, using temperatures above 70°C but below 100°C,
permits controlled growth of gadolinium oxycarbonate (Gd2O(CO3)2 • H2O) amorphous
particles (general mechanism elucidated in equations 1-4), while avoiding secondary
nucleation events. Previous work has shown that lower urea concentrations
([urea]/[Gd3+]<45) generally results in fewer individual nuclei, and polydisperse size
distribution. As the concentration increases ([urea]/[Gd3+]>90), there is a larger number of
individual seeds formed via burst nucleation, and a smaller average diameter after the
growth period.[35] In this reaction scheme there is a ~240x molar excess of urea to Eu(NO3)3
and Gd(NO3)3 combined.
𝑘

𝐻2 𝑁 − 𝐶𝑂 − 𝑁𝐻2 → 𝑁𝐻3 + 𝐻𝐶𝑁𝑂 ↔ 𝑁𝐻4+ + 𝑁𝐶𝑂−

(1)

𝑁𝐶𝑂− + 2𝐻2 𝑂 ↔ 𝑁𝐻4+ + 𝐶𝑂32−

(2)

2+
𝑀(𝐻2 𝑂)3+
+ 𝐻3 𝑂+
𝑛 + 𝐻2 𝑂 ↔ [𝑀(𝑂𝐻)(𝐻2 𝑂)𝑛−1 ]

(3)

[𝑀(𝑂𝐻)(𝐻2 𝑂)𝑛−1 ]2+ + 𝐶𝑂32− → [𝑀(𝑂𝐻)𝐶𝑂3 (𝐻2 𝑂)] + (𝑛 − 2)𝐻2 𝑂

(4)

Where 𝑀 = 𝐸𝑢3+ , 𝐺𝑑 3+
The Gd2O(CO3)2 • H2O:Eu3+ can be directly converted to Gd2O3:Eu3+ via
calcination under atmosphere at 600°C, then converted to Gd2O2S:Eu3+ via sulfidation with
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elemental sulfur under argon flow at 700°C. However, the brightness of these particles can
be substantially increased by first encapsulating a sintering agent.[36] Sodium fluoride
(NaF) is incorporated into the crystal structure to act as a sintering agent, minimize defects,
and increase crystal domain size after initial precipitation and growth of particles. To
prevent particle fusion during calcination and sulfidation, a protective shell of Gd2O(CO3)2
• H2O:Eu3+ is co-precipitated on the surface after incorporation of fluoride ions.[19] The
target Gd2O2S:Eu3+ is obtained by oxidation of the precursor in air at 600°C, followed by
sulfidation of the oxide under inert argon atmosphere at 700°C, which is a typical synthetic
strategy.[19,28]
3.3.2 Gd2O2S:Eu3+ Nanoparticle Characterization
Size analysis of nanoparticle samples is done via transmission electron microscope
image analysis. A total of 18 TEM images and 1565 individual nanoparticles are measured
and grouped into bins according to diameter in Figure 3.1c. Based on this analysis, the
mean particle diameter is approximately 120 nm, with a distribution of sizes between 6157 nm. Despite efforts to reproduce previous reported synthetic methods[19], our particles
are polydisperse with average diameter is over 100 nm. This could be due to additional
nucleation events occurring during the encapsulation step after incorporation of NaF. The
second co-precipitation step is intended to deposit a protective amorphous shell onto the
surface of previously synthesized particles, but it is probable that some of the precursor is
nucleating as Gd2O(CO3)2 • H2O:Eu3+ particles (without the NaF dopant).
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X-Ray excited optical luminescence emission of synthesized particles is ~1.4%
commercial particles, determined via comparison of 30 mg samples of each material. The
crystalline domain average size is estimated from the powder XRD data using the Scherrer
equation (equation 5):
𝐾𝜆

(5)

𝐷 = 𝛽×cos 𝜃

Where D is the mean crystal domain size, K is a dimensionless shape factor (0.90),
λ is the wavelength for X-Ray (~0.154 nm), β is the peak broadening (in radians) at full
width half maximum (FWHM), and θ is the diffraction angle. Based on analysis of peaks
with local maxima at 2θ=26.8°, 30.0°, and 38.2°, the average crystal domain size is
determined to be 56.2 nm. With average particle diameter being ~120 nm, luminescence
efficiency is likely hindered by crystal defects at grain boundaries within individual
particles, in addition to point defects and site defects on particle surface.[19] Nonetheless,
particles synthesized by this method are visibly luminescent, and appropriate for
subsequent functionalization.

3.4 Nanophosphor Functionalization
Nanophosphors used in this study, for functionalization and imaging, are from a
more recent synthesis performed by Dr. Sriparna Bhattacharya and Basanta Ghimire.
XEOL and XRD characterization are unavailable, but luminescence is verified
qualitatively via UV excitation. TEM images confirm spherical, nanoscale morphology
(Figure 3.2).
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Figure 3.2. Schematic illustrating the functionalization of synthesized nanoparticles. First step is SilanePEG5000-Biotin conjugation to the nanoparticle surface. Second step is the attachment of streptavidin
labeled anti-vancomycin IgM via streptavidin-biotin bond. Third step is the addition of 3H-vancomycin.
Fourth step illustrates the concept that, in solution, bound 3H-vancomycin will excite luminescence in
Gd2O2S:Eu3+ particles, while particles in the absence of 3H-vancomycin will not luminesce.

3.4.1 Silane-PEG5000-Biotin Functionalization and Verification
The goal of this functionalization procedure is to attach anti-vancomycin IgM to
the surface of Gd2O2S:Eu3+ nanoparticles (Figure 3.2). IgM functionalized nanoparticles
will bind free vancomycin (and 3H-vancomycin) stimulate luminescence emission. First,
silane-PEG5000-biotin is attached to the surface of synthesized Gd2O2S:Eu3+
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nanoparticles. Particles have previously been coated with tetraethyl orthosilicate (TEOS),
in a solution of ethanol and distilled water, as an intermediate step for amine
functionalization of Gd2O2S:Eu3+ and Y2O2S:Yb/Er.[19] A similar reaction approach is used
to attach the silicate moiety to the positively charged Gd2O2S:Eu3+ nanoparticles, in step
one of the functionalization procedure. This attachment is verified using streptavidin
labeled microbubbles (Figure 3.3). Streptavidin labeled microbubbles bind the free biotin
moieties on synthesized nanoparticles, causing the labeled nanoparticles to float to the top
of the buffer solution. When illuminated with UV (~395 nm), the red luminescence from
nanophosphors is visible by eye in the microbubble layer at the top of the centrifuge tube.
By contrast, when unlabeled particles are added to a solution of streptavidin labeled
microbubbles, the nanoparticles form a pellet at the bottom of the centrifuge tube.

Figure 3.3. a) Illustration of streptavidin labeled buoyant microbubble (Akadeum Life Sciences) bound to
biotin labeled Gd2O2S:Eu3+ nanoparticle. b) Experimental design for verification of biotin labeling.
Successfully labeled nanoparticles will bind buoyant microbubbles and float along the top of buffer filled
centrifuge tube. Unlabeled particles should form a pellet at the bottom of the tube. c) Photograph of biotin
labeled particles in left-most tube, and unlabeled control particles in right-most tube. Luminescence is
evidence in the microbubble layer of the left-most tube, indicating successful conjugation of biotin to
nanoparticles. Control tube exhibits luminescent pellet at the bottom.
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3.4.2 Anti-Vancomycin IgM Functionalization
Streptavidin has an incredibly high binding affinity for biotin, exhibiting a
dissociation constant of ~10-14 mol/L, and is a common motif in bio-nanotechnology due
its ease of application in functionalization strategies.[37–39]

For this reason, our

functionalization strategy aims to conjugate streptavidin to anti-vancomycin IgM antibody
for easy attachment to biotin labeled nanoparticles. Streptavidin labeling of antivancomycin IgM is performed using a streptavidin labeling kit that acts upon the amine
group in lysine residues (details are proprietary information from Abcam). Based on the
calculated area of an IgM molecule, which has an approximate extended diameter of ~30
nm, approximately 64 antibodies can fit within the surface area of a 120 nm diameter
nanoparticle.[40] This functionalization protocol aimed to add ~16 IgM per particle, which
is well under the maximum feasible amount. IgM is a pentameric antibody, with the ability
to bind 10 antigens (vancomycin, in this case). As a result, roughly 150 3H-vancomycin
molecules should be able to bind to each particle.

3.5 Nanoparticle Luminescence Signal vs 3H-Vancomycin Concentration
To evaluate anti-vancomycin IgM conjugation, 1 mg of silane-PEG5000-biotin
functionalized particles are added to 5 separate wells in a 96-microwell plate. In each 1 mg
sample, if 150 3H-vancomycin molecules bind each particle, then the addition of 2.4x1013
vancomycin molecules would theoretically saturate all available epitope binding sites. The
commercially obtained 3H-vancomycin has an activity of 27.5 Ci/mmol, so 2.4x1013
vancomycin molecules corresponds to an activity of 1.1 µCi. Therefore, the concentration
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gradient added to the wells is 0, 0.05, 0.1, 0.25, and 0.5 µCi, to prevent saturation of binding
sites and ensure that a change in luminescence would be visible with increasing 3Hvancomycin concentration.
Initially the plate is imaged with 200 µL of buffer present in each well, but there is
not a significant luminescence signal when the particles are suspended in liquid. As a result,
the buffer solution was evaporated from the wells and imaged again (Figure 3.4). When
the wells are dried, the nanoparticles exhibit a linear increase in luminescence signal with
increase in 3H-vancomycin concentration (R2=0.99). This demonstrates the feasibility of
imaging

changes

in

radiolabeled

drug

concentrations

using

radioluminescent

nanoparticles. The lack of luminescence signal in nanoparticle suspension is currently
under investigation. When there is liquid present, if vancomycin is not directly bound to
anti-vancomycin functionalized nanoparticles, the free 3H-vancomycin beta-decay range
is too short (~0.4 µm average path length in water) to excite luminescence from
nanoparticles.[41,42] Biotin labeling of particles appears to have been successful, so the
subsequent streptavidin labeling of anti-vancomycin IgM and attachment to biotin labeled
particles may not have been successful.
Though no tissue was present for initial experiments, we can detect changes in drug
concentration on the order of nanograms, using only 1 mg nanoparticles, and 300 s
exposure time. Luminescence is evident only in the presence of 3H-vancomycin, confirmed
by the lack of luminescence in well containing only 1 mg nanoparticles. Based on standard
deviation of background (Sb), and the slope of the linear regression line from the
concentration gradient (m) we find a limit of detection (LOD) of 7.8 nCi (LOD = 3*Sy/m
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= 7.8 nCi = 0.4 ng vancomycin). Our previous study, using tritium excited microphosphors
to detect drug release from an immobilized Gd2O2S:Eu3+ film, demonstrates that the
integrated luminescence signal decreases by a factor of ~7.6 when imaging through 5 mm
porcine muscle tissue.[2] As a result, we expect the limit of detection for this method to
increase when imaging through tissue, but signal decrease can be partially mitigated by
using longer exposure time, higher luminescence efficiency nanoparticles, and higher
concentrations of both nanoparticles and drug.

Figure 3.4. a) Luminescence image of synthesized Gd2O2S:Eu3+ nanoparticles with increasing 3HVancomycin concentration from left to right. Each well contains 1 mg particles. Image collected with IVIS
Lumina using an exposure time of 300 s and plotted as pseudo-color image using MATLAB. Color bar
represents relative luminescence intensity. b) Luminescent regions of interest (ROIs) plotted vs. amount of
vancomycin (ng).
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3.6 Methods
3.6.1 Gd2O2S:Eu3+ Nanoparticle Synthesis
1. Synthesis of Gd2O(CO3)2 Precursor: Gadolinium (III) nitrate (Gd(NO3)3•6H2O)
and europium nitrate (Eu(NO3)3•6H2O) solutions are prepared with DI water at
concentrations of 1 M and 80 mM, respectively (Alfa Aesar, Haverhill, MA). 2 mL of 1M
Gd(NO3)3, 625 µL 80 mM Eu(NO3)3, and 1.2 g polyvinylpyrrolidone (PVP K-30, MW
40,000, Spectrum Chemicals, Gardena, CA) added to a 2 L DI water in a round bottom
flask. Flask is placed in an appropriately sized (2 L) heating mantle and heated to 80 °C
using an Inkbird temperature controller and thermocouple (Shenzhen, China) with constant
stirring (using a magnetic stir bar). Once solution reaches 80 °C, 30 g urea is added to the
solution (4111-05, J.T. Baker, Phillipsburg, NJ). Reaction is removed from heat as soon as
solution becomes cloudy (approximately 30 minutes) and placed immediately in an ice
water bath to quench reaction. Once cooled to 25°C, particles are collected by
centrifugation at 15,000 RCF for 10 minutes. Particles are washed 3x with DI water and
1x with ethanol.
2. Sodium Fluoride (NaF) Doping: Particles are resuspended in 10 mL DI water
and sonicated with 5 mg NaF for five minutes (A13019, Alfa Aesar, Haverhill, MA). 30
mL glycerol (BDH1172, BDH Chemicals, Poole, UK) is added and the mixture is
subsequently heated to 120°C for 2 hours to evaporate water. The mixture is then heated
to 170°C for 1 hour under nitrogen in a vacuum oven to calcine and encapsulate NaF. Once
cool, particles are collected by centrifugation at 15,000 RCF and washed 3 x with DI water.
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3. Preparation of Protective Shell on NaF Doped Precursor: Amorphous particles
are resuspended in 200 mL DI water with 1.2 g PVP and heated to 80°C. 2 mL 1M
Gd(NO3)3, 1 mL 80 mM Eu(NO3)3, and 12 g urea are then added to the solution. Solution
is kept stirring for 1 hour, then quenched with an ice bath. Particles are collected via
centrifugation at 15,000 RCF, washed 3x with DI water, and 1x with ethanol. Dry particles
in an oven for 3 hours at 80°C to evaporate remaining solvent.
4. Conversion to Gd2O3:Eu3+, then Gd2O2S:Eu3+: Dry particles are transferred to a
ceramic combustion boat and calcined in a muffle furnace for 2 hours at 600°C. This
process converts Gd2O(CO3)2 precursor to Gd2O3:Eu3+. Sample, still in the combustion
boat, is then placed in a high purity quartz process tube (OD 60 mm, L 1000 mm, open
both ends, Across International, Livingston, NJ) with excess sulfur powder (10785, Alfa
Aesar, Haverhill, MA). Tube is placed in a tube furnace at 700°C for 1 hour, with argon
flow. Once cool, particles are incubated in 200 mL DI water to remove residual sulfur and
gadolinium sulfide. Particles collected using centrifugation (15,000 RCF).
Nanoparticles used for the following functionalization steps are synthesized using
an identical co-precipitation method. The sulfidation step, however, is performed using
molar equivalent of sodium thiosulfate (Na2SO3•5H2O), as opposed to elemental sulfur in
excess . Nanoparticles are ground together with Na2SO3•5H2O, transferred to a combustion
boat, and placed in a muffle furnace at 1000°C for 1 hour. Once cool, particles are washed
3x with DI and collected via centrifugation (15,000 RCF).
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3.6.2 Nanoparticle Characterization
Transmission electron microscopy (TEM) was performed using an H7600 with an
accelerating voltage of 120 kV. 18 Images (1565 total particles) collected at 100,000x
magnification were analyzed using ImageJ software. Images are first converted to binary
(black and white) via threshold adjustment. “Watershed” feature is used to separate
particles that are touching, although images with minimal particle overlap are selected for
size analysis. “Analyze Particles” is used to estimate diameter. Particle diameters are
plotted as a histogram in Excel.
Powder X-Ray diffraction (XRD) is performed using a Rigaku diffractometer (40
kV, 40 mA, CuKα X-Ray target and radiation). Measurements collected at 2θ values
between 15-80°. Crystal domain size is calculated using the Scherrer equation, based on
XRD peak full-width half-max.
X-Ray excited optical luminescence characterization performed using a Leica DMI
5000 microscope (Wetzlar, Germany), coupled with a DNS 300 spectrometer (DeltaNu,
Laramie, WY). X-Ray source operated at a voltage of 40 kV and current of 99 µA (MiniX X-Ray tube, Amptek Inc., Bedford, MA). For comparison of commercial particles
(Gd2O2S:Eu3+ 8 µm median diameter, part number UKL63/N-R1, Phosphor Technology
LTD, Stevenage, UK), 30 mg of synthesized and commercial particles are deposited into
separate wells in a transparent 96-microwell plate, and spectra are collected using an
exposure time of 1 s.
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3.6.3 Biotin Functionalization of Nanoparticles
20 mg of Gd2O2S:Eu3+ particles first washed 3x in 50 mL DI water, and 1x in 50 mL 95%
ethanol (UN1170, Pharmco by Greenfield Global, Brookfield, CT, USA). For wash steps,
particles are centrifuged at 5000 RCF for 10 minutes, and supernatant is removed using an
electronic pipette controller (MSP3000, MedSupply Partners, Atlanta, GA, USA). Particles
are then resuspended in 40 mL 1x phosphate buffered saline (PBS) to a final concentration
of 2 mg/mL, at pH 7.5 (P4417-50TAB, Sigma-Aldrich, St. Louis, MO, USA).
Measurement of pH is performed using pH indicator strips (Indicator Paper pH 4.510,2614-991, Whatman™ GE Healthcare Companies, Buckinghamshire, UK).
PEGylation solution is made using 95% ethanol, at a concentration of 1 mg/mL
(Silane-PEG-Biotin MW5000, 10285-5000-1g, Nanosoft Polymers, Winston-Salem, NC,
USA). 10 mL of 1mg/mL washed Gd2O2S:Eu3+ 2.5 µm diameter particles, and 30 µL of 1
mg/mL PEG solution are added to a 15 mL Teflon centrifuge tube for PEGylation of
particles. Sample tube is placed on a 360° sample rotator for 1 hour at room temperature
(~25°C) (VWR® Tube Rotator, 10136-084, Radnor, PA, USA). The particles are washed
3x with DI water, with centrifugation at 500 RCF for 10 minutes per cycle, then
resuspended in 10 mL of pH 7.5 1x PBS buffer (concentration 1 mg/mL).
PEG to particle ratio was determined by calculating the surface area of a particle
and supposing ~1 silane-PEG-biotin molecule could bind per nm2. The surface area for 1
particle, based on a mean diameter of 120 nm, is calculated to be 4.52x104 nm2. This
corresponds to 4.52x104 PEG molecules per particle, which stoichiometrically converts to
7.5x10-20 mol PEG per particle. Based on the density of Gd2O2S (7.34 g/cm3)[43], and the
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calculated volume of a single particle (9.0x10-16 cm3), each particle has an approximate
mass of 6.5x10-15 g. Therefore, in a sample of 10 mg, there are approximately 1.5x1012
individual particles. Knowing the moles of PEG required per particle (7.5x10-20), the
number of Gd2O2S:Eu3+ particles in a 10 mg sample (1.5x1012), and the approximate
molecular weight of silane PEG biotin (5000 g/mol), we calculate that 574 µg of silane
PEG biotin will provide enough surface coverage. Therefore, we add 600 µL of 1 mg/mL
PEG solution to 10 mL of 1 mg/mL Gd2O2S:Eu3+.
3.6.4 Buoyant Microbubble Verification of Biotin Functionalization
Streptavidin microbubbles and separation buffer purchased from Akadeum Life Sciences
(SKU: 1110-000, Akadeum Life Sciences, Ann Arbor, MI). 50 µL of 1 mg/mL biotin
labeled Gd2O2S:Eu3+¸ and 50 µL microbubbles are added to 1 mL separation buffer.
Control is made using same proportions of microbubbles, separation buffer, and
nanoparticles (unlabeled). Solutions are placed on 360° rotator for 5 minutes, then allowed
to separate for 30 minutes. Image (figure 3.3) taken from the side using standard phone
camera, with UV illumination (~395 nm) positioned ~15 cm above open centrifuge tubes.

83

3.6.5 Streptavidin Labeling of Anti-Vancomycin

Figure 3.5. Schematic illustration for streptavidin conjugation to anti-vancomycin IgM. Figure adapted from
Abcam instructional booklet.

Mouse Anti-Vancomycin antibodies (IgM) (MCA5746G, BIO-RAD, Hercules, CA, USA)
are labeled with streptavidin using a streptavidin conjugation kit (ab102921, Abcam, Cambridge,
MA, USA). Frozen materials are first brought to room temperature (~25°C). 100 µg (1 mg/mL)

anti-vancomycin IgM is transferred to a 2 mL, low-binding, centrifuge tube. 10 µL of
“modifier” are added to the solution and gently agitated. The solution is transferred to the
vial of streptavidin conjugation mix and combined via drawing solution into the pipette
and dispensing 3 times. The vial is wrapped in foil and left at room temperature for 3 hours
to complete conjugation. 10 µL of “quencher” are added to the solution to stop reaction.
The solution is ready to use after 30 minutes.
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3.6.6 Anti-Vancomycin IgM Labeling of Nanoparticles
10 mg silane-PEG-biotin coated microparticles from section 3.6.2 are transferred to a fresh 15 mL
centrifuge tube. 20 µL (1 mg/mL) of streptavidin labeled anti-vancomycin IgM is the added to the
tube. Sample is gently inverted three times then placed in the fridge at 4°C for 12 hours. Amount

of anti-vancomycin IgM to add is determined by estimating the number of particles in a 10
mg sample. Number of particles is estimated using the volume of a single particle
(V=4/3πr3) and density of gadolinium oxysulfide (7.34 g/cm3). A target value of 16
antibody molecules per 120 nm particle is used. This is based on the calculated area of an
IgM antibody (~707 nm2), of which approximately 64 fit within the surface area of a single
120 nm particle (4.5x104 nm2) . Number of antibodies is converted to mass using the
average molecular weight for IgM antibodies (~900 kDa).[44] After 12 hours, particles settle
naturally. Supernatant is carefully removed using a graduated plastic pipette.
Functionalized particles are reconstituted in pH 7.5 PBS at a concentration of 5 mg/mL.

3.6.7 3H-Vancomycin Gradient Preparation, Imaging, and Analysis
200 µL (5 mg/mL) nanoparticles from section 3.6.5 are deposited into neighboring
wells (D4-D8) in a an Optiplate-96, opaque white 96-well microplate (Perkin Elmer,
Waltham, MA). 0, 10, 20, 50, and 100 µL (5 µCi/ mL) 3H-vancomycin standard are then
deposited to create concentration gradient. Radioluminescence images are acquired on a
small animal imager (IVIS Lumina XR, Perkin Elmer, Waltham, MA) under luminescence
collection only (no photograph). F/stop of 1, medium binning, field of view (FOV) B, and
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300 s exposure acquisition settings are used. Luminescence image is then processed and
analyzed using custom MATLAB scripts. 20x25 pixel regions of interest (ROIs) are
identified, using “Data Tips” feature, for each of the five wells in the concentration
gradient. 10 background ROIs (20x25 pixels) are also measured from regions within the
same image surrounding the luminescent

wells. Standard deviation of the

blank/background (Sy) is calculated based on these values. Slope of the linear regression
line (m) of total, background corrected, luminescence intensity vs. concentration of
vancomycin is used, along with Sy, to calculate limit of detection according to equation 6:
𝑆𝑦

(6)

𝐿𝑂𝐷 = 3 × 𝑚

3.7 Conclusions
The goal of this work is to establish proof of concept for using radioluminescent
Gd2O2S:Eu3+ nanoparticles to monitor radiolabeled drug loading and release. First,
radioluminescent Gd2O2S:Eu3+ doped nanoparticles (~120 nm) have been synthesized via
coprecipitation of gadolinium and europium nitrate salts under decomposition of urea.
Characterization of nanoparticles indicates that the average crystal domain size is 56.2 nm,
and X-Ray excited optical luminescence is approximately 1.4% of commercial
microparticle luminescence intensity, based on spectra acquired under the same conditions.
Particles synthesized using a nearly identical method (alternative sulfidation step)
are functionalized with silane-PEG5000-biotin. Functionalization is confirmed using
buoyant streptavidin labeled microbubbles. Anti-vancomycin IgM is conjugated with
streptavidin and intended to attach to biotin labeled nanoparticles via streptavidin-biotin
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bond. Conjugation step appears to be unsuccessful because addition of 3H-vancomycin to
nanoparticles suspended in buffer solution do not result in a luminescence signal. However,
when suspension is dried, we observe a linear relationship between luminescence intensity
and concentration of radiolabeled drug. Successful streptavidin labeling of antivancomycin IgM, and subsequent attachment to biotin labeled particles, is expected to
generate a similar response in aqueous suspension.
This method is intended for use in monitoring drug loading and release, in vivo.
While this study demonstrates the concept for application with the antibiotic vancomycin,
the approach is generalizable for any pharmaceutical appropriate for delivery via
nanocarrier. For imaging in vivo, X-Ray luminescence tomography (XLT) can be a used to
calibrate nanoparticle luminescence signal in tandem with radiolabeled analyte
luminescence.[45,46] Imaging radiolabeled drug release from radioluminescent nanoparticles
is more complicated than imaging drug release from a stationary, implanted film of
radioluminescent Gd2O2S:Eu3+. An immobilized film can be characterized prior to
implantation, and a reference region can be incorporated into the sensor design to account
for luminescence perturbations due to tissue.[2] Part of the advantage of nanomedicine is
the ability to non-invasively achieve local drug delivery. However, this also means that the
number of nanoparticles that reach the target location is dependent on a variety of factors
that largely depend on individual patient biology. To achieve quantitative drug
measurements, the luminescence signal due to presence of radiolabeled drug will need to
be calculated ratiometrically in comparison to the luminescence signal evident under X-
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Ray of known energy. To achieve this, the luminescence signal can be collected via XLT
with and without X-Ray excitation.
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CHAPTER 4
DEVELOPMENT OF PH SENSITIVE FILM FOR OPTICAL DETECTION OF
IMPLANT ASSOCIATED INFECTION VIA ULTRASOUND LUMINESCENT
CHEMICAL IMAGING (ULCI)
4.1 Abstract
We have developed an ultrasound luminescent, pH sensitive film and imaging
method for early detection of implant associated bacterial infection. The film consists of
mechanoluminescent europium and dysprosium doped strontium aluminate (SrAl2O4:Eu,
Dy) microphosphors immobilized in a polymer film (either polydimethyl siloxane or
hydrophilic polyurethane). After brief excitation with UV (~395 nm) light, a focused
ultrasound beam generates an ~18x increase in luminescence intensity of the SrAl2O4:Eu,
Dy film at the ultrasound focal point. By pulsing the ultrasound ON and OFF, the
luminescence can be modulated and exploited for imaging. To impart pH sensitivity, first
Krylon™ spray paint, and eventually nile red fluorescent dye, is used to shift SrAl2O4:Eu,
Dy luminescence emission to overlap with pH sensitive dye, bromothymol blue, absorption
at pH 8. As pH decreases from pH 8.0 to pH 6.0, bromothymol blue transmits more
SrAl2O4:Eu, Dy excited nile red fluorescence emission. Decrease in pH manifests as an
increase in luminescence intensity, which is first characterized using a spectrometer, then
imaged using a novel Ultrasound Luminescent Chemical Imaging (ULCI) technique.
Results demonstrate that our film(s) are sensitive to biologically relevant changes in pH,
and can be imaged through tissue mimicking, light scattering media.
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4.2 Introduction
In the past 10 years, there has been an upsurge in development and application of
implanted medical devices, including heart valves, pacemakers, stents, orthopedic rods,
screws, plates, hernia mesh, and prosthetic joints. Biomedical implants have improved and
extended the quality of life for patients, but implant associated infection continues to be a
concern. About 5-10% of the 2 million fracture fixation surgeries performed each year
result in implant associated infection.[1] In war trauma related fractures and treatment
scenarios, infection is reported to be as high as 40%.[2] The severity of infection depends
on a multitude of risk factors including smoking, diabetes, immunosuppressed states, and
revision surgeries for previously infected implants.[3,4] Early detection of implant
associated infection is of paramount importance for maximizing treatment efficacy. For
example, if infection is diagnosed within four weeks of device implantation, surgical
debridement of the implant surface and administration of antibiotics is often sufficient to
eradicate infection. Infections diagnosed after this initial timeframe commonly require
device removal to eradicate infection, which is because bacterial biofilms exhibit increased
resistance to antibiotics the longer they are permitted to grow.[5–7] Device removal is
expensive and painful for patients, and there is an increased risk of re-infection from
additional surgery and hospitalization. Earlier detection of implant infection may reduce
the need for invasive treatment. In addition, probing the biochemical environment at the
implant surface can guide efforts to develop therapeutics capable of targeting biofilms with
reduced antibiotic susceptibility.
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Infection specific imaging has been done using radiolabeled probes, imaged with
either positron emission tomography (PET) or single-photon emission computed
tomography (SPECT). However, these techniques are expensive, and require close
proximity to radiochemical synthesis facilities containing a cyclotron.[8] Alternative
imaging modalities that do not use radiopharmaceutical contrast agents, such as computed
tomography (CT), magnetic resonance imaging (MRI), ultrasound, and X-Ray projection
imaging, can provide excellent spatial resolution but lack the chemical sensitivity required
for early diagnosis of infection.[9]
One promising avenue for early detection of infection is to monitor pH at the
implant surface. Surface pH is a promising analyte because inflammation and infection can
cause local acidosis. Acidosis is a well-documented product of bacterial metabolic
fermentation and respiration (i.e., lactic and carbonic acid produced in glycolysis) , and
bacterial colonies have been shown to produce a local acidic environment in vitro.[10] This
acidic environment is suspected to play a role in reduced antibiotic susceptibility of
biofilms, along with other factors such as nutrient limitation and insufficient antibiotic
penetration.[5] As a result, there has been a concerted effort to develop methods to detect
pH at the biomedical implant surface, in vivo. One such optical method is X-Ray Excited
Luminescent Chemical Imaging (XELCI). This imaging modality exploits scintillators that
emit visible light when excited by ionizing radiation (e.g., X-Rays). In this approach, light
from X-Ray luminescent scintillators passes through a pH sensitive film that alters the
spectrum and can be detected through tissue. Mapping of pH is done by scanning the
sample, point-by-point, relative to a stationary X-Ray source and light collection optics.
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The spectrum at each point is used to generate an image. The spatial resolution of this
technique is limited, primarily, by the X-Ray beam width. This approach produces high
resolution images that contain local biochemical information about the implant surface.
Some drawbacks of this technique, however, are the necessity of a relatively expensive
focused X-Ray source, and the associated radiation dose that limits repeated
measurements.[8]
Herein we describe Ultrasound Luminescent Chemical Imaging (ULCI), which is
designed for monitoring pH, in vivo, as an early indication of implant associated infection
(Figure 4.1).[11] The scanning technique and image generation is similar to XELCI but uses
a pulsed ultrasound source to excite a mechanoluminescent pH sensor instead of a focused
X-Ray beam. Traditionally ultrasound imaging is used as a complementary diagnostic tool
to capture structural images through biological tissues. Ultrasound is a lucrative optical
excitation source because it is non-ionizing, and scatters less than light in biological
tissues.[12] However, ultrasound alone does not provide the biochemical information
necessary to measure pH, and monitor local infection. To impart biochemical sensitivity,
an ultrasound luminescent film is paired with a pH sensitive dye. Specifically, SrAl2O4:
Eu, Dy is a mechanoluminescent material that emits luminescence, with a maximum at
~522 nm, in response to mechanical stimulation such as ultrasound. This emission is
attributed to the 4f65d-4f7 electronic transition of Eu2+ ions in SrAl2O4: Eu.[13] This
emission is red shifted using, first, fluorescent spray paint, and later nile red fluorescent
dye. After shifting the emission to >605 nm, the mechanoluminescence overlaps with
absorption of pH sensitive bromothymol blue at pH 8 (~627 nm). As a result, pH is mapped
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by scanning the UL film relative to a fixed ultrasound source and light collection optics.
As pH becomes more acidic, the bromothymol blue film transmits more luminescence,
manifesting as an increase in luminescence with decreasing pH.

Figure 4.1 Illustration of ULCI pH sensor design and application. Sensor is attached to fracture fixation
implant on a fractured bone. Focused ultrasound excites the film, point-by-point, and light is collected by a
liquid light guide. Sensor Design: Green luminescence of SrAl2O4:Eu,Dy is shifted, using red dye, to overlap
absorption of pH sensitive dye. As a result, phosphorescence is modulated by pH sensitive dye. Growth of
bacterial biofilm generates an acidic environment, which causes the pH sensitive film to turn yellow. Yellow
film transmits more luminescence, resulting in higher transmittance of luminescence emission. Blue/green
color film, associated with physiological and basic pH, transmits less luminescence emission. pH is
monitored as a function of luminescence emission intensity.
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4.3. Optical Characterization of Ultrasound Modulated Mechanoluminescent Film
After exciting a polydimethyl siloxane (PDMS) encapsulated SrAl2O4:Eu, Dy
microphosphor film with UV light, an ultrasound beam pulse produces a bright spot in the
film (Figure 4.2a). SrAl2O4:Eu, Dy is a mechanoluminescent material and emits light when
stimulated by ultrasound. The emission can be turned ON and OFF by pulsing the
ultrasound beam as a function of time. When the ultrasound pulses ON, the spot is visible
and exhibits higher emission intensity, and when it is switched OFF the emission decreases
and the spot is no longer visible to the naked eye (Figure 4.2b-c). Moreover, the
luminescence intensity increases by a factor of ~18 when the ultrasound is pulsed ON when
compared to the spectra taken while the ultrasound is pulsed OFF.
Upon examination of the spectral data, we noticed a ~10 nm blue shift in the
luminescence spectrum of SrAl2O4:Eu, Dy under ultrasound excitation compared to the
afterglow emission seen after UV excitation. Typical afterglow emission spectra of
SrAl2O4:Eu, Dy show an emission maximum at 522 nm, while the spectrum under
ultrasound excitation is 512 nm. A blue shift suggests that emission is occurring from a
higher energy state than with UV excitation alone. The mechanism for phosphorescence
involves absorption of excitation energy, followed by intersystem crossing to an excited
triplet state, from which long lived phosphorescence is emitted as electrons transition back
to the singlet ground state.[14,15] A possibility is that the introduction of energy from the
focused ultrasound beam is sufficient to excite the electrons to a slightly higher energy
state before relaxation. This 10 nm blue shift in luminescence emission is noteworthy for
optimization of pH sensor film and imaging.
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4.4 Target Imaging using ULCI Scanner

Figure 4.2 a) Depicts ultrasound excited luminescence of SrAl2O4:Eu, Dy embedded in PDMS. The
ultrasound source is a focused beam incident on the film, visible as a bright spot. b) Plot shows SrAl2O4:Eu,
Dy film behavior as ultrasound is pulsed on and off. After initial excitation with 395 nm light, ultrasound
excitation produces an 18x increase in luminescence intensity compared to when the ultrasound is switched
off.[13] c) Shows luminescence intensity as a function of time. Phosphorescence of this material increases
rapidly with ultrasound excitation, and decays exponentially once ultrasound is turned off. [13]

The ULCI scanning system is a modified version of the setup used for the X-Ray
excited luminescent chemical imaging system, which is described elsewhere.[10,16,17] The
SrAl2O4:Eu, Dy film is secured to the bottom of a glass dish, and placed on an X-Y
moveable stage (Figure 4.3a). The ultrasound probe and liquid light guide are held
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stationary while the sample is raster scanned in X-Y directions relative to these
components. The ultrasound probe is controlled by a function generator, which pulses the
ultrasound at a chosen frequency. The liquid light guide collects light emitted from the
SrAl2O4:Eu, Dy film and delivers it to a 50/50 beam splitter, which splits the signal between
two photomultiplier tubes (PMTs) that contain optical filters (625 nm, and 705 nm
bandpass filters, in this case). To evaluate knife-edge spatial resolution, shapes are formed
with black electrical tape overtop of the SrAl2O4:Eu, Dy film.
SrAl2O4:Eu, Dy requires excitation with UV (395 nm) light, and the film emits long
lasting afterglow without ultrasound excitation. The afterglow dissipates exponentially
with time, and if our ultrasound source were to be continuously ON we would be unable to
distinguish between background afterglow luminescence and ultrasound modulated
luminescence. This is especially true for targets larger than the ultrasound focal point/spot
size. The combined background luminescence can be higher than the luminescence from
the ultrasound excited region. By pulsing the ultrasound ON and OFF, we are able to
distinguish between the blinking, ultrasound modulated signal, and the signal attributed to
background afterglow luminescence. The vertical lines apparent in the ULCI images depict
ultrasound modulation. In the intensity vs linear position plot (Figure 4.3c) the ultrasound
modulation manifests as relative increases and decreases in luminescence intensity, which
allow us to distinguish ultrasound modulated luminescence from background
luminescence. This modulation pattern is not seen in the regions where black tape is placed.
As shown in Figure 4.3, triangular and rectangular shapes can be resolved using ultrasound
excitation and point-by-point raster scanning. The spatial resolution is essentially limited,
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in the current setup, by focused ultrasound spot size. Based on the speed of sound in water
(cs=1530 m s-1) and the ultrasound transducer frequency (ν=1.1 MHz), the wavelength (λ)
is calculated to be 0.14 cm. We calculate the diffraction limited spot size using the
following equations (equation 1):
𝜆

(1)

𝐵𝐷 = 0.62 sin 𝜃

Where BD is the minimum resolvable beam diameter, λ is ultrasound wavelength,
and θ is the half-angle.[18] Based on an approximate half angle of 22° (0.38 rad), and the
wavelength of our ultrasound in water (λ=0.14 cm), we calculate a diffraction limited spot
size of 1.7 mm. Our current focused ultrasound source exhibits a spot size of approximately
0.3 cm (Figure 4.2), so we have significant room for imaging resolution improvement. We
may also achieve a smaller spot size by using a higher frequency ultrasound source (e.g.
10 MHz ultrasound source would yield a beam diameter of 0.2 mm). However, highfrequency ultrasound waves are more attenuated in biological tissues than lower frequency
ultrasound waves.[19]
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Figure 4.3 a) Depicts ULCI setup for target scanning. The ultrasound probe and liquid light guide are held
stationary over the sample, which is attached to a container on the motorized stage. The liquid light guide is
fed to the optical filters and PMTs contained in the 50/50 beam splitter. Information from PMTs is fed to a
data acquisition board, then sent to a computer for image display using LabVIEW and MATLAB. b) Shows
triangular SrAl2O4:Eu, Dy target, created with black electrical tape, and corresponding ULCI image. c)
Shows triangular and square targets created on a film of SrAl2O4:Eu, Dy using black electrical tape. Part b)
shows the corresponding ULCI image, and c) is a plot of intensity vs. linear position taken from b) in the
region indicated by the red dotted line. Ultrasound modulation is seen in this graph as temporary increases
in luminescence above background.[13]

101

4.5 pH Sensing with 2-Layers: UL and pH Sensitive Films
4.5.1 Strontium Aluminate with Krylon™ Paint, and pH Sensitive PEG Hydrogel

Figure 4.4 PDMS encapsulated SrAl2O4:Eu, Dy before and after 3 coats of Krylon™ cerise fluorescent spray
paint. Plots depict the UV (395 nm) excited luminescence emission spectra, with emission intensity displayed
on the left-most Y-axes. This is overlaid with the absorption profile for bromothymol blue, pH sensitive dye,
at pH 5 (yellow) and pH 8 (green). Absorbance values are displayed on the right-most Y-axes. These plots
demonstrate that modification of the SrAl2O4:Eu, Dy film with Krylon™ spray paint shifts emission to
overlap with bromothymol blue absorption at pH 8. [13]

Local acidosis can be an indicator of bacterial growth on biomedical implant
surfaces. As a result, we tuned our ultrasound luminescent imaging methodology to be able
to detect chemical changes such as pH. As proof of principle, cerise (pink) colored
Krylon™ spray paint was coated on top of the SrAl2O4:Eu, Dy and PDMS film to shift the
luminescence emission to overlap with the absorption of a pH sensitive dye, bromothymol
blue (Figure 4.4). Bromothymol blue is sensitive to pH range 5-8, which is appropriate for
biological application and measurement of localized acidosis. At pH ~8, bromothymol blue
appears green, and primarily absorbs light ~627 nm. At pH 4, bromothymol blue appears
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yellow, and absorbs light ~ 474 nm. SrAl2O4:Eu, Dy exhibits a luminescence maximum at
~522 nm. When coated with pink Krylon™ spray paint, the luminescence emission is
absorbed, and fluorescence is emitted by the paint at ~607 nm. This emission wavelength
overlaps with the absorption maximum of bromothymol blue at pH 8 (Figure 4.4). When
the surrounding medium is at a higher pH, more of the luminescence emission is absorbed
by the bromothymol blue dye. As a result, when a hydrogel impregnated with bromothymol
blue is placed on top of the Krylon™ coated SrAl2O4:Eu, Dy film, the luminescence
intensity decreases as pH increases. This is because when the bromothymol blue film is
under acidic conditions, it does not absorb as much of the luminescence emission when
compared to more basic conditions. The pH modulated luminescence intensity at a given
wavelength (LpH) can be estimated according to the following relationship between percent
transmittance of bromothymol blue at a given pH (%T) and unmodulated luminescence
intensity (L) at that wavelength (Equation 2). %T is related to total absorbance (At) and
can be written in terms of concentration of deprotonated bromothymol blue (Cin-) and
protonated bromothymol blue (CHin), using Beer-Lambert Law (A=εbC, where ε is the
molar absorptivity coefficient, b is the path length, and C is the concentration) (Equations
3 & 4). Concentrations of protonated and deprotonated pH indicator (BTB) can be
calculated using the Henderson-Hasselbalch equation, inputting the pH value and the pKa
(~7.5) (Equation 5).
𝐿𝑝𝐻 = %𝑇 × 𝐿

(2)

%𝑇 = 10−𝐴

(3)

𝐴𝑡 = (𝜀𝑖𝑛- 𝑏𝐶𝑖𝑛- ) + (𝜀𝐻𝑖𝑛 𝑏𝐶𝐻𝑖𝑛 )

(4)
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𝐶𝑖𝑛-

= 10𝑝H−𝑝Ka

(5)

𝐹 = 𝐶𝑖𝑛- + 𝐶𝐻𝑖𝑛

(6)

10𝑝H−𝑝Ka ×𝐹

(7)

𝐶𝐻𝑖𝑛

𝐶𝑖𝑛- = 1+10𝑝H−𝑝Ka

𝑝H−𝑝Ka

(𝜀 ×10
)+𝜀𝐻𝑖𝑛
)
−𝑏𝐹( 𝑖𝑛1+10𝑝H−𝑝Ka

𝐿𝑝𝐻 = (10

)×𝐿

(8)

The total formal concentration of bromothymol blue indicator (F) consists of the
sum of deprotonated (Cin-) and protonated (CHin) components. Equations 5 and 6 are
combined to give Cin- as a function of pH, pKa, and F in Equation 7. Equations 2-7 are
then combined in Equation 8 to give luminescence intensity (at a given wavelength) as a
function of underlying luminescence spectrum, F, b, ε for protonated and deprotonated
BTB, pH, and pKa. This equation demonstrates that we can calculate the amount of
protonated and deprotonated BTB species by measuring pH, and inputting the total formal
concentration (F). The signal saturates at low and high pH values, but exhibits sensitive
color change (and luminescence modulation) within one pH unit of the pKa value (~7.5, if
we assume one discrete pKa value). A higher pH yields a higher concentration of
deprotonated BTB (Cin-) and will result in a higher absorbance of longer wavelengths. In
other words, as pH increases, the SrAl2O4:Eu, Dy luminescence transmission decreases.
This is seen clearly in Figure 4.5a, where the luminescence spectra of the Krylon™ coated
SrAl2O4:Eu, Dy film is collected as it passes through the pH sensitive bromothymol blue
hydrogel at pH’s between 4-9. We note, however, that the response occurs over a wider pH
range than expected for the free BTB dye. This suggests that there are a range of
microenvironments within the film that cause a spread in local pKa. This is an advantage
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when interested in looking at a wider pH range, but reduces sensitivity near the free dye’s
pKa. Nonetheless, the luminescence emission intensity, under consistent UV excitation, is
highest at low pH (pH 4) and lowest at high pH (pH 9).
The pH sensor film, which also contains a control region of hydrogel without
bromothymol blue, was imaged in a solution of coffee creamer (~1.0 g/L) to simulate light
scattering in biological tissue. Figure 4.5d-e shows images at pH 4 and pH 9, using
ultrasound modulated frequency of 2 Hz, with a scan speed of 1 mm/s. The pH sensitive

Figure 4.5 a) Plot depicts changes in luminescence intensity of Krylon™ coated SrAl 2O4:Eu, Dy film
modulated by bromothymol blue pH sensitive dye impregnated PEG hydrogel target at pH 4.0-9.0. b)
Schematic of film fabrication: SrAl2O4:Eu, Dy film is coated with Krylon™ spray paint, the bromothymol
blue PEG hydrogel is attached on top using cyanoacrylate glue. c) Image of pH sensor. Left-most hydrogel
contains bromothymol blue, and rightmost gel does not (control gel). Hydrogel targets only cover a portion
of the Krylon™ coated SrAl2O4:Eu, Dy film. d) ULCI image at pH 4. e) ULCI image at pH 9. Vertical lines
evident in these images are due to ultrasound modulation at 2 Hz (1 mm/s scan rate). [13]
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target is clearly distinguishable, in comparison to the control target, from background.
Furthermore, the target at pH 9 appears darker, according to the luminescence color map,
when compared to the target in the image at pH 4. The decrease is luminescence with
increase in pH is consistent with the spectroscopic data shown in Figure 4.5a.
The use of Krylon™ spray paint to red shift SrAl2O4:Eu, Dy film was successful,
but impractical for application in vivo. Spray paint contains toxic hydrocarbons such as
toluene, benzene, and xylene, which are associated with increased risk of renal tubular
acidosis, hypokalemic paralysis, and various hematological disorders.[20,21] While it is
possible to encapsulate spray paint in the PDMS film with SrAl2O4:Eu, Dy, thereby
circumventing issues associated with leaching and toxicity, the fluorescent dye used in the
Krylon™ spray paint is considered proprietary information. This affects the ability to
reproduce data in the future, as the exact paint recipe is unknown. As a result, alternative
dyes are investigated in the following section(s) that similarly shift the SrAl2O4:Eu, Dy
luminescence emission spectrum.
Another challenge with this approach is the attachment of the hydrogel pH sensitive
target to the paint coated SrAl2O4:Eu, Dy film. The hydrogel is structurally brittle, and
difficult to attach to the film without breaking. In the images for Figure 4.5, the hydrogel
is attached to the luminescent film using household superglue. Occasionally the superglue
interacts with the pH sensitive target, preventing reliable pH response and color change.
Ideally, the goal is to make a pH sensitive, ultrasound luminescent film, that contains all
the necessary components in a single layer. The next section discusses an intermediate step
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where an alternative, flexible, hydrophilic polyurethane is used as an alternative to both
PDMS and the PEG hydrogel.
4.5.2 Strontium Aluminate with Nile Red, and pH Sensitive Hydrophilic Polyurethane Film

Figure 4.6 HydroMed™ D3 encapsulated SrAl2O4:Eu, Dy with and without nile red fluorescent dye. Plots
depict the UV (395 nm) excited luminescence emission spectra, with emission intensity displayed on the leftmost Y-axes. This is overlaid with the absorption profile for bromothymol blue, pH sensitive dye, at pH 5
(yellow) and pH 8 (green). Absorbance values are displayed on the right-most Y-axes. These plots
demonstrate that modification of the SrAl2O4:Eu, Dy film with nile red shifts emission to overlap with
bromothymol blue absorption at pH 8.

Nile red (9-(Diethylamino)-5H-benzo[a]phenoxazin-5-one) is a solvatochromic
dye, which means the shape and spectral position of absorption and emission bands vary
(up to 100 nm) with solvent. Specifically, nile red excitation and emission spectra shift
toward shorter wavelengths as solvent polarity decreases.[22–24] This phenomenon is seen
in fluorescent compounds that have aromatic rings with polar substituents, details of which
have been explored elsewhere.[25] When a polar solvent (i.e., ethanol) is used to deposit a
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film of HydroMedTM D3 (hydrophilic polyurethane), SrAl2O4:Eu, Dy, and nile red, the
absorption of nile red overlaps sufficiently with emission of SrAl2O4:Eu, Dy. As a result,
the fluorescence maximum of nile red in the UL film is observed to be at ~624 nm,
compared to ~522 nm luminescence with SrAl2O4:Eu, Dy alone (Figure 4.6). The
fluorescence of nile red overlaps with absorption of pH sensitive bromothymol blue at pH
8 (~627 nm), which makes nile red an appropriate replacement for the KrylonTM cerise
spray paint.
To impart pH sensitivity, the bromothymol blue film was made using HydroMedTM
D3, instead of the PEG hydrogel (described in previous section). As expected, this film is
much more flexible and easier to manipulate without tearing or fracturing. Initially this
film was directly deposited onto the UL film containing nile red (sealed with PDMS), with
the expectation that the two separate films would adhere to one another. However, this was
not seen to be the case once the films were submerged in buffer. The topmost film,
containing only HydroMedTM D3 and bromothymol blue, detached once the polymer
absorbed water. As a result, the film needed to be attached using cyanoacrylate glue on
either side of the film. Once secured with glue over-top of the UL film, the bromothymol
blue film stayed in place and the color change was uniform after 5 minutes when transferred
from PBS buffer at pH 5 (yellow) to new PBS buffer at pH 8 (dark green) (Figure 4.7c).
While the dye is uniformly distributed throughout the film, the film itself exhibits visible
striations and puckering (evident in the photos). However, the emission intensity decreases
as pH increases, which is consistent with our expectation (Figure 4.7a-b).
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Figure 4.7 a) Plot depicts changes in luminescence intensity of nile red and SrAl 2O4:Eu, Dy film modulated
by HydroMed™ D3 film containing bromothymol blue pH sensitive dye at pH 5.0-9.0. b) Plot depicting the
change in luminescence at 632 nm (the fluorescence maximum for nile red) vs. pH c) Images of 2-layer pH
sensor. Left-most image shows the yellow color of bromothymol blue at pH 5, and the right-most image
shows the green color at pH 8.

109

4.6 All-In-One pH Sensing Films
4.6.1 Characterization of Nile Red for All-In-One Film

Figure 4.8 Demonstrates the effect of aqueous solution and pH on nile red dye. a) HydroMed™ D3 film
with nile red before equilibration (dry). b) Luminescence spectra of nile red film dry, and at pH 5,7, and 9.
Spectra acquired immediately after switching UV excitation source OFF. c) nile red film after 30 minutes of
equilibration at pH 9. d) Wavelength region 450-555 nm from spectrum plotted in b), expanded to see subtle
differences. Slight red shift in nile red fluorescence from 503 nm to 510 nm at pH 5, 508 nm at pH 7, and
506 nm at pH 9. e) Wavelength region 600-670 nm from spectrum plotted in b), expanded to see subtle
differences. Slight red shift in nile red fluorescence from 624 nm to 638 nm at pH 5, 7, and 9.

110

Due to the solvatochromic properties of nile red, the previous iteration of ULCI
film involves sealing the HydroMedTM D3 + SrAl2O4:Eu, Dy + nile red film with PDMS
to prevent shifts in the absorption and emission spectra in different aqueous (pH)
environments. The pH sensitive bromothymol blue film was attached separately, and the
pH sensitive layer is the only layer that needs to change colors. However, to make a pH
sensitive film that contains all necessary components within a single layer, the behavior of
nile red in HydroMedTM D3 (with SrAl2O4:Eu, Dy) needs to be characterized at different
pH’s.
The HydroMed™ D3 nile red film, containing SrAl2O4:Eu, Dy, exhibits emission
maxima at 503 nm and 624 nm before submersion in buffer (dry). Immediately after
submersion in pH 5 buffer, the film changes from a deep pink color to a more pastel purple
color. After equilibration in buffer for 30 minutes, the color does not change dramatically
from pH from 5 to 9. The 503 nm peak shifts to 510 nm at pH 5, 508 nm at pH 7, and 506
nm at pH 9. The primary peak at 624 nm, which is the region of luminescence modulated
by bromothymol blue, shifts to 638 nm at pH 5, then stays at 638 nm from pH 7-9. The
absorption maximum for bromothymol blue at pH 8 is ~627 nm, so the red shift in emission
maximum of nile red means there is less overlap between the fluorescence and absorption.
This could translate to a less dramatic change in luminescence intensity with pH than seen
with the nile red film sealed in PDMS. However, the shift is not dramatic enough to prevent
this film design from working and the advantages of an all-in-one film outweigh the
potential drawbacks. Additionally, once the film is equilibrated in aqueous solution (of any
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pH studied), the emission remains consistent at 638 nm. Nile red, within our target pH
range, remains an appropriate choice to shift the emission spectrum of SrAl2O4:Eu, Dy.
4.6.2 All-In-One Film

Figure 4.9 a) Plot depicts changes in luminescence intensity of all-in-one HydroMed™ D3, nile red,
SrAl2O4:Eu, Dy, bromothymol blue pH sensitive film at pH 6.0-9.0. UV left ON for spectra acquisition b)
Plot depicting the change in luminescence at 638 nm (the fluorescence maximum for nile red after
equilibration in water) vs. pH for UV ON c) Plot depicts changes in luminescence intensity of all-in-one
HydroMed™ D3, nile red, SrAl2O4:Eu, Dy, bromothymol blue pH sensitive film at pH 6.0-9.0. UV turned
OFF for spectra acquisition. d) Plot depicting the change in luminescence at 638 nm (the fluorescence
maximum for nile red after equilibration in water) vs. pH for UV OFF.

In Figure 4.9 the all-in-one film response to pH 6.0-9.0 is demonstrated by taking
luminescence spectra, with and without UV, after equilibration in various buffer solutions.
Spectra acquired with UV OFF have lower emission intensity overall, which is because the
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afterglow of SrAl2O4:Eu, Dy decays exponentially with time (Figure 4.2c). Because the
pH response of this film is based on changes in luminescence intensity, the time between
switching the UV flashlight off and collecting spectrum needs to be consistent for each pH
spectrum collected. For this reason, the characterization is compared with spectra taken
while the UV light remains ON. For both UV ON and UV OFF, the emission intensity at
638 nm decreases as pH increases. The wavelength 638 nm is chosen because this is the
fluorescence maximum determined for nile red within this pH range (section 5.6.1). As
expected, the bromothymol blue dye absorbs more of the luminescence emission as it
changes from yellow to green (i.e., as pH increases). Despite the 14 nm red shift in nile red
fluorescence, the all-in-one film behaves in a similar manner to the 2-part films described
in section 5.5 and is most sensitive to changes between pH 6.0 and 8.0. Normal muscle
tissues have relatively neutral pH (between 7.0-7.4), and a study of implant surface pH
during infection (using microelectrodes) showed that pH dropped to ~6.0.[26] Therefore,
this film is sensitive within the correct range to measure biologically relevant pH for
localized acidosis.
The film is imaged at pH’s 6.0 and 9.0 using ULCI scanner as shown in figure 4.10.
According to the color map generated in MATLAB, the luminescence intensity is ~5x
brighter at pH 6.0, when compared to pH 9.0. The luminescence in the control target
remains the same at each pH value. The control target in these experiments contains only
HydroMedTM D3 and SrAl2O4:Eu, Dy, but a more appropriate control should also contain
nile red dye. Nile red is intended to impart a consistent red shift in the UL emission of
SrAl2O4, but the subtle solvatochromic shifts (Figure 4.8) can be accounted for by adding
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nile red to the control region in the future. However, the images acquired in this experiment
are more blurred than previously acquired images (i.e. 2-part ULCI film in section 4.5.1,
figure 4.5). The ultrasound modulation is also difficult to identify if it is present at all. One
possible explanation for this is the new target holder made using a laminating pouch. The
advantage of this target holder is that the circular window allows circulation of surrounding
liquid both above and below the film, without the need for cyanoacrylate adhesive. This
design may not hold the UL pH sensor film as rigidly as when a glass slide is beneath the
film for support, as is the case for the 2-part films shown in section 5.5. In addition, the
behavior of the focused mist-maker ultrasound is inconsistent, and eventually stopped
working during experimentation. The ULCI images may not be ultrasound modulated if
the ultrasound was not pulsing as it was programmed to, which means the images reflect
SrAl2O4:Eu, Dy afterglow from UV excitation only. This makes distinction between target
and background difficult. Nonetheless, the film behaves as expected and the ULCI images
still reflect a change in luminescence intensity consistent with increase in surrounding pH.
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Figure 4.10 Laminating pouch sample holder with windows punched through the front and back layers. Film
is held in place around the outer circumference, exposing both films to surrounding medium. The front of
the laminating pouch is covered in black duct tape. Left-most film contains only HydroMedTM and strontium
aluminate. Right-most film contains HydroMedTM, strontium aluminate, nile red fluorescent dye, and
bromocresol blue pH sensitive dye. a) Depicts film after equilibration at pH 6. b) Depicts film after
equilibration at pH 9. Left-most control film does not change color with pH. c) ULCI image taken of the
sensor at pH 6, from the front side. d) ULCI image taken of the sensor at pH 9, from the front side.

4.7 Methods
4.7.1 Preparation of UL film
Polydimethyl siloxane (PDMS) (Sylgard 184 Silicone Elastomer base and curing
agent, DOW, Midland, MI, USA) is prepared in a 10:1 ratio (base: curing agent). The
PDMS mixture is then combined in a 1:2 ratio, by mass, with SrAl2O4:Eu, Dy
mechanoluminescent powder (756539-25G, Sigma Aldrich, St. Louis, MO, USA). The
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mixture is whipped for 10 minutes, then poured onto a substrate, usually a glass microscope
slide, for curing. After pouring, the film is placed in a vacuum chamber for 30 minutes to
remove excess air bubbles. To cure PDMS, the film is placed in the oven at 80°C for 1
hour. The film, prepared in this way, was used for initial ULCI testing and characterization
(figure 4.2 and 4.3)

4.7.2 Acquisition of Ultrasound Excited Luminescence Spectra with Time Decay
Film is placed face down on the microscope stage (DMI 5000, Leica Microsystems,
Germany), centered over the objective lens. The film is first irradiated from the top with a
UV flashlight (395 nm, EscoLite, La Palma, CA, USA), held using a ring stand and clamp,
~ 10 cm from the sample in a perpendicular orientation. For spectra acquisition, a focused
ultrasound beam is incident on the UL film, which is generated by a mist-maker removed
from a basic humidifier (unknown make and model). Ultrasound spot size is approximately
3 mm in diameter. The ultrasound is pulsed at a frequency of 2 Hz. A 5X objective lens
directs light to a spectrometer (DNS 300, DeltaNu, Laramie, WY, USA) to collect spectral
data. Kinetic spectra acquisition is used for this experiment with 0.15 s exposure time for
a total of 50 seconds.

4.7.3 Application of Krylon™ Spray Paint
To red shift the SrAl2O4:Eu, Dy emission for overlap with bromothymol blue (pH
sensitive dye) absorption, 3 coats of pink, fluorescent spray paint (Krylon Fluorescent
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Spray Paint-Cerise, Cleveland, OH, USA) are applied overtop of the cured PDMS/
SrAl2O4:Eu, Dy film. Each coat was dried for 3 hours at room temperature (~25 °C). Before
attachment of pH sensitive hydrogel, the painted film was placed in the oven at 80°C for
12 hours to evaporate any remaining solvent.
An alternative method for preparing this film is to incorporate the spray paint into
the film, instead of applying paint over top of the film. To do this, 3 coats of paint are
applied directly to SrAl2O4:Eu, Dy powder. Once dry, the powder and paint are ground
together using a mortar and pestle. The SrAl2O4:Eu, Dy/fluorescent paint mixture can then
be added to PDMS in the same ratio as described above. The advantage to this method is
that the toxic paint is encapsulated by the biocompatible PDMS.

4.7.4 Preparation of pH Sensitive PEG Hydrogel
The hydrogel is prepared with 35 weight % acrylamide monomer (01696-100G,
Sigma-Aldrich, St. Louis, MO, USA), 35 weight % poly(ethylene glycol) diacrylate
(PEGDA- Mn 700) chemical cross-linker (455008-100ML, Sigma-Aldrich, St. Louis, MO,
USA), 1 weight % 2,2-dimethoxy-2-phenyl acetophenone (DMPA) (196118-50G, SigmaAldrich, St. Louis, MO, USA), 0.5 weight % bromothymol blue pH indicator dye (1144135G, Sigma-Aldrich, St. Louis, MO, USA), and deionized water. All materials are brought
to room temperature (~25°C) prior to mixing. Once warmed to room temperature, each
component is used as received. An example recipe for 5 g total: 1.75 g acrylamide
monomer, 1.75 g PEGDA-700, 25 mg of bromothymol blue, 50 mg DMPA, and 1.425 g
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deionized water. The mixture is combined using a 360° sample rotator for 3 hours. The
solution is then injected into a mold, which is fabricated using a rectangular silicone spacer
(400 µm thickness), sandwiched between two 3-inch x 3-inch flint glass plates, clamped
together using three binder clips (one on the left, right, and bottom edges). Prior to mold
fabrication and injection of polymer solution, the glass plates are soaked in a glass cleaning
solution composed of 50 g/L sodium hydroxide (NaOH) in 50% Ethanol for 12 hours, then
rinsed with DI water and dried in the oven at 80°C for 30 minutes. The mold, containing
polymer solution, is placed into a nitrogen purged glove box (2100-4-C, Cleatech LLC,
Santa Ana, CA, USA) for 2 hours. Photo-polymerization is then performed using UV
irradiation (~368 nm) for 10 minutes. After polymerization, the hydrogel is removed from
the mold by soaking in deionized water. Once removed from the mold, the hydrogel is
cycled between 70% ethanol and deionized water each day for four consecutive days (this
serves to remove excess monomer, unreacted initiator, and unadhered dye molecules).
Once this process is complete, the hydrogel is stored in pH 7 phosphate buffered saline.
For preparation of the control hydrogel, the same process is used. The only difference is
bromothymol blue is not added to the mixture, and the difference in mass is accounted for
by adding additional deionized water (i.e., for the 5 g recipe above, 1.450 g water would
be added instead of 1.425 g).
To attach the polymerized hydrogel to the UL film, the gels are cut using a circular
hole cutter (3/8 inch diameter), then adhered using cyanoacrylate (Gorilla Super Glue Gel,
The Gorilla Glue Company, Cincinnati, OH, USA).
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4.7.5 Preparation of HydroMed™ D3 Film with SrAl2O4:Eu, Dy and Nile Red
HydroMedTM D3 (AdvanSource Biomaterials Corp, Wilmington, MA, USA) is an
ether-based hydrophilic polyurethane designed for coating biomedical implants. This
material was chosen because it can be used to immobilize SrAl2O4:Eu, Dy particles, and is
appropriate for incorporation of Nile Red fluorescent dye (N0659, TCI America, Portland,
OR, USA). All recipe calculations are based on the total volume of solvent (95% ethanol)
chosen and does not account for volume changes due to the addition of individual
components. First HydroMedTM D3 (120 mg/mL) is added to ethanol. The mixture is
placed on a 360° sample rotator for 24 hours to completely dissolve polymer. The following
components are added once HydroMedTM is dissolved: SrAl2O4:Eu, Dy (300 mg/mL), and
Nile Red (0.08 mg/mL). An example recipe is 0.75 g SrAl2O4:Eu, Dy, 0.3 g HydroMedTM
D3, 2.5 mL ethanol (95%), and 200 µL Nile Red (1 mg/mL in acetone). The mixture is
then placed on the 360° sample rotator for 3 hours, to ensure homogeneous combination of
all components. The mixture is then carefully poured onto a glass microscope slide and
placed into a vacuum chamber for 12 hours to evacuate air bubbles and evaporate solvent.
Because Nile Red is a solvatochromic compound, the film must be sealed before
placing it into solution to maintain consistent fluorescence properties. PDMS is combined
in a 10:1 ratio (base: curing agent) by mass. The mixture is whipped for 10 minutes, then
placed in a vacuum chamber to evacuate air bubbles. The PDMS is then thinly spread over
top of the SrAl2O4:Eu, Dy/Nile Red/HydroMedTM film using a spatula. The film is then
placed in the oven at 80°C for 1 hour to cure.
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4.7.6 Preparation of HydroMed™D3 film with pH Sensitive Bromothymol Blue
All recipe calculations are based on the total volume of solvent (95% ethanol) chosen and
does not account for volume changes due to the addition of individual components. First
HydroMedTM D3 (120 mg/mL) is added to ethanol. The mixture is placed on a 360° sample
rotator for 24 hours to completely dissolve polymer. Bromothymol blue is added at a
concentration of 1.44 mg/mL. An example recipe is 0.3 g HydroMed™ D3, 2.5 mL 95%
ethanol, and 600 µL (6 mg/mL in ethanol) bromothymol blue. The mixture is placed on the
360° sample rotator for an additional 3 hours to ensure homogenous distribution of
bromothymol blue throughout the polymer mixture. The mixture is then carefully poured
onto a glass microscope slide and placed into a vacuum chamber for 12 hours to evacuate
air bubbles and evaporate ethanol.
To detach film from glass slide, it is submerged in pH 5 buffer for 30 minutes. Once
detached, film is carefully dried using a Kimwipe (KIMTECH™, Roswell, GA, USA), and
secured over-top of the UL film using cyanoacrylate glue on the left and right outer edges.

4.7.7 Characterization of Nile Red Film
Nile red film is prepared as described in 5.4.4 section of Methods. Film is then placed, face
down, on the microscope stage (DMI 5000, Leica Microsystems, Germany), centered over
the objective lens. The film is irradiated from the top with a UV flashlight (395 nm,
EscoLite, La Palma, CA, USA), held using a ring stand and clamp, ~ 10 cm from the sample
in a perpendicular orientation. A 5X objective lens directs light to a spectrometer (DNS
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300, DeltaNu, Laramie, WY, USA) to collect spectral data. An exposure time of 0.01 s is
used, and the spectra is collected immediately after UV flashlight is switched off (to collect
fluorescence only from nile red excited by SrAl2O4:Eu, Dy, and eliminate any direct
excitation of the nile red dye by UV). A background spectrum is collected in the same way,
and subtracted from the fluorescence spectra, manually, in Microsoft Excel. Each spectrum
is plotted as an average of three spectra acquired back-to-back. To obtain spectra of the
film at pH 5, 7, and 9, the film is submerged in the corresponding phosphate buffered saline
(Standard Buffer, BDH LLC, Minneapolis, MN, USA) solution for 30 minutes prior to
acquiring spectra. Measurement of pH is done with a pH electrode (Mettler Toledo InLab®
Routine Pro, Columbus, OH) and pH meter (6230 N JENCO, San Diego, CA), calibrated
at pH 4.0, 7.0, and 10.0.

4.7.8 Preparation of All-in-One pH Sensitive ULCI film
All recipe calculations are based on the total volume of solvent (dichloromethane)
chosen and does not account for volume changes due to the addition of individual
components. To fabricate the pH sensitive all-in-one target, HydroMedTM D3 (120 mg/mL)
is first added to dichloromethane. The mixture is placed on a 360° sample rotator for 24
hours to completely dissolve polymer. The following components are added once
HydroMedTM is dissolved: SrAl2O4:Eu, Dy (300 mg/mL), Nile Red (0.04 mg/mL), and
bromothymol blue (0.6 mg/mL). An example recipe is 3 g SrAl2O4:Eu, Dy, 1.2 g
HydroMedTM D3, 10 mL dichloromethane, 400 µL Nile Red (1 mg/mL in acetone), and 1
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mL bromothymol blue in ethanol (6 mg/mL). The mixture is then placed on the 360°
sample rotator for 3 hours, to ensure homogeneous combination of all components. The
mixture is then carefully poured onto a glass microscope slide and placed into a vacuum
chamber for 12 hours to evacuate air bubbles and evaporate solvent. To remove film from
glass slide, the film and slide are placed into a petri dish with pH 7 phosphate buffered
saline for 3 hours. The film automatically detaches from the glass slide as it absorbs water.
To fabricate the control film the same recipe is used, without the addition of Nile
red and bromothymol blue dyes. An example recipe is 3 g SrAl2O4: Eu, Dy, 1.2 g
HydroMedTM D3, and 10 mL dichloromethane. The mixture is then placed on the 360°
sample rotator for 3 hours, to ensure homogeneous combination of all components. Then
the mixture is carefully poured onto a glass microscope slide and placed into a vacuum
chamber for 12 hours to evacuate air bubbles and evaporate solvent. To remove film from
glass slide, the film and slide are placed into a petri dish with pH 7 phosphate buffered
saline for 3 hours. The film automatically detaches from the glass slide as it absorbs water.
The target holder is fabricated using a self-sealing laminating pouch (LS851-10G.
ScotchTM Self-Sealing Laminating Pouches, Business Card Size, 2-inch x 3.5 inches, 3M,
St. Paul, MN, USA). The target windows are created before placing the films into the
laminating pouch. First, black duct tape is applied to the front side of the laminating pouch
in a single layer (Duck 1265013 Black Color Duct Tape, Duck Brand, Avon, OH, USA).
This serves to block luminescence from any film in the laminating pouch that is not in the
defined target window. To generate the target windows, a single hole punch is used to
create two holes (8 mm in diameter, each). The holes are punched through the front and
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back layers of the laminating pouch. The pH sensitive film, and control film, are roughly
cut into ~10 mm diameter circles and placed inside the laminating pouch, centered over the
target window (on the back side of the laminating pouch). The protective sheet on the inside
of the top layer is removed and carefully applied to the bottom layer, over the two films
still centered over the target window. This target holder design serves to hold the UL films
in place at the edges (without the use of cyanoacrylate glue), hold the targets stationary
while they are submerged in pH buffer for ULCI scanning, and expose films to changing
pH in surrounding fluid (which permits color change in pH sensitive film).

4.7.9 pH Sensor Response Characterization
ULCI film response to pH was characterized using the same Leica microscope and
DeltaNu spectrometer described in section 5.4.7 of Methods. Figure 4.11 is a schematic
of the setup, with the separate UL film and pH sensitive PEG hydrogel target as an example.
The target is placed face down on the microscope stage, so the UV flashlight irradiates the
UL film from underneath, and the light collected by the objective is only the light that has
passed through the pH sensitive target. A black piece of carboard, with a hole the same size
and shape as the target, is used to block UV and fluorescent light from the UL film that has
not passed through the pH sensitive target.
For the UL film coated with cerise Krylon™ spray paint, and the pH sensitive PEG
hydrogel, spectra are acquired at pH’s 4.0, 6.0, 6.5, 7.0, 7.5, 8.0, and 9.0. The film was
submerged in the corresponding buffer (Standard Buffer, BDH) for 30 minutes prior to
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Figure 4.11 Depicts microscope setup for characterization of pH sensitive ultrasound luminescent films. UL
film is deposited onto glass slide, followed by deposition of pH sensitive film. Film is centered face down
over the microscope objective so that UV excitation is incident on the UL film from above, luminescence
passes through the pH sensitive film, and the pH modulated luminescence signal passes through the objective
and collected by the spectrometer from below.

spectra acquisition to ensure complete color change of pH sensitive target. An exposure
time of 0.005 s was used. Spectra are normalized to 700 nm from pH 4.
For the HydroMed™ D3 2-part film, containing nile red and bromothymol blue
layers, spectra are acquired at pH’s 5.0, 6.0, 7.0, 7.5, 8.0, 8.5, and 9.0. The film was
submerged in the corresponding buffer (Standard Buffer, BDH) for 30 minutes prior to
spectra acquisition to ensure complete color change of pH sensitive target. An exposure
time of 0.00003 s was used. Spectra are normalized to 750 nm from pH 7.5.
For the all-in-one film, spectra are acquired at pH’s 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, and
9.0. The film was submerged in the corresponding buffer (Standard Buffer, BDH) for 30
minutes prior to spectra acquisition to ensure complete color change of pH sensitive target.
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An exposure time of 0.05 s was used. Measurement of pH for each experiment is done
using the pH electrode and meter described in section 5.4.6 of Methods. Spectra are
normalized to the intensity of pH 6.5 at 475 nm, and 3 iterations of gaussian smoothing are
performed (averaged over a window size of 3).

4.7.10 ULCI Scanning and pH Mapping
ULCI film is first attached to the bottom of an 8” x 8” glass dish (Easy Grab Baking
Dish, Pyrex®, Corning, NY, USA) using Scotch tape, then filled with 1.5 L PBS (P4417100TAB, Sigma Aldrich, St. Louis, MO, USA). The pH of this solution is adjusted using
0.1 M hydrochloric acid (HCl) and 0.1 M sodium hydroxide (NaOH). Measurement of pH
for each experiment is done using the pH electrode and meter described in section 5.4.6 of
Methods. To mimic scattering effects of biological tissue, powdered coffee creamer is
added to the solution (1 g/L) (Coffee-Mate Original Powder Coffee Creamer, Nestle,
Arlington, VA, USA).
The scanning system itself is a modified version of setup used for XELCI.. The
glass dish is positioned on an x-y motorized stage (Models: LTS300 and LTS150, Thorlabs
Inc., Newton, NJ, USA) such that the sample is aligned with ultrasound focus and light
collection optics. Below the transparent platform of the stage, UV LED strip lights (385400 nm) are taped to charge the UL film prior to scanning (Ontesik 20 ft LED Black Light
Strip Kit, Amazon, Seattle, WA, USA) (figure 4.12). The collimated ultrasound beam is
generated by a mist-maker with approximately 3 mm diameter spot size. Initial testing was
done using the mist-maker removed from a basic humidifier (unknown make and model),
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and later iterations of testing use a mist/fog maker (Aluminum Mist Maker, AGPTEK,
Brooklyn, NY, USA) purchased individually. Light is collected using a liquid light guide
(Model 77638, Newport Corporation, Irvine, CA, USA) attached to a 50/50 beam splitter
containing photomultiplier tubes (PMTs) (Model P25PC-16, SensTech, Surrey, UK) with
625 nm and 705 nm band-pass filters. The beam splitter is an artifact of the XELCI setup,
and the readout from 620 nm filter is the signal used to generate images in this study (figure
4.12). PMT pulses are counted with a data acquisition board (DAQ) (NI cDAQ™-9171,
National Instruments, Austin, TX, USA). The stage is controlled with a custom program
written in LabVIEW (National Instruments, Austin, TX, USA). This program also records
PMT output and position of stage versus time, displaying the image as it is being acquired.
More nuanced description of the scanning system can be found in previously published
work.[16]
For image acquisition and scanning, the film is first charged with the UV strip lights
for 1 minute, and imaging is initiated 30 s after switching the UV lights off. The mistmaker/ultrasound and liquid light guide are held stationary while the sample inside the
glass dish is raster scanned using the stage beneath (figure 4.3a). A scan speed of 1 mm/s
is used. All imaging components are housed inside a light tight box, with controls outside
the box. Images are exported and analyzed using custom MATLAB scripts.
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Figure 4.12 a) UV strip lights secured beneath the ULCI scanning setup for consistent excitation before
each scan. b) and c) Depict luminescence spectrum of all-in-one film with and without 625 nm filter. 625
nm filter is used in collection optics for ULCI scanning setup to collect pH modulated signal.

4.7.11 Ultrasound Modulation

Ultrasound output is pulsed by switching the direct current to the transducer on and
off, using a field-effect transistor (FET) (IRFP260N, Infineon Technologies, Neubiberg,
Germany). The FET is coupled in series on the ground leg of a 24 V, direct current, power
supply. This allows the FET to have ground reference, thereby simplifying connection to
external function generator (DS345, Stanford Research Systems, Sunnyvale, CA, USA).
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The function generator is programmed to output a square wave with 5 V amplitude, and
frequency of 2 Hz.[11]
4.8 Conclusions and Future Work
We designed a series of ultrasound luminescent, pH sensitive films, which were
imaged in aqueous media using ULCI scanning. 2-layer films, with primary layer
containing mechanoluminescent SrAl2O4:Eu, Dy and either Krylon™ fluorescent spray
paint or nile red fluorescent dye, and secondary layer containing pH sensitive bromothymol
blue, show sensitive pH response between 6.0 and 8.0. However, attachment of the two
layers to one another has proven difficult. As a result, we developed an all-in-one pH sensor
film. This film contains HydroMed™ D3, SrAl2O4:Eu, Dy, nile red, and bromothymol
blue. After characterization of solvatochromic nile red at pH’s 5, 7 and 9, we found that
the shifted signal at 638 nm is modulated effectively by bromothymol blue. This film is
sensitive to changes in pH between 6.0-8.0 and is easy to fabricate.
While our findings are promising, there are various avenues for improvement. One
example is the challenge of finding a reliable, inexpensive, focused ultrasound source.
Initial testing was done using the mist-maker component of a commercial humidifier, but
this is not reproducible. We have purchased inexpensive mist-makers, and modified the
electronic components for controlled pulsing, but these sources either burn out within a
few days, or do not produce a focused spot appropriate for ULCI imaging. We are currently
working to identify and fix these issues in the ultrasound sources we have and are also
seeking new sources.
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For imaging in aqueous scattering media (tissue mimic), we used a concentration
of 1 g/L powdered coffee creamer. 1 g/L is an approximate concentration of 0.1%, and
literature states that 3.5% milk has a scattering coefficient (25.0 cm-1) comparable to skin
epidermis (30.0 cm-1) and well above that of muscle (7.5 cm-1) and whole blood (12.0 cm1

). To have a more accurate representation of the effect of biological tissue, Intralipid (1%)

or a higher fat % milk product may be used in the future. In addition, black India Ink (0.3
µL/mL) can be added to mimic absorption properties of tissue.[27]
Lastly, we plan to optimize the optical setup and collection efficiency, as well as
determine the best ultrasound pulse frequency for imaging. We are currently using a 50/50
beam splitter with filters optimized for use with Gd2O2S:Eu3+, which has emission peaks
at ~620 nm and 700 nm. The 50/50 beam splitter will be more useful with an alternative
filter that collects light within a region of the SrAl2O4:Eu, Dy spectrum independent of
changes in pH. For example, in addition to the 625 nm filter that collects the pH modulated
signal, a filter in the 475 nm or 750 nm could potentially serve as a reference. The ratio of
reference wavelength emission to pH modulated wavelength emission can be used to
account for scattering and absorption due to the presence of biological tissue (or mimics).
In addition, positioning of the liquid light guide and ultrasound source can be optimized
with respect to excitation and collection efficiency. A custom holder can then be fabricated
to maintain optimized positioning and aid reproducibility.
This series of studies demonstrates proof of concept for an ultrasound luminescence
based chemical imaging methodology, applied for imaging changes in pH. Localized
acidosis is associated with implant associated infection, and an ultrasound-based method
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to probe the chemical environment of the implant surface would be useful to detect
infection at an early stage. With improvement to sensor design, light collection, and
imaging setup, we hope to investigate this sensor in an animal model of infection in the
future.
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CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS

In this dissertation we describe methods to make chemical measurements, through
tissue, using phosphorescent materials. Crystalline phosphorescent materials, such as
Gd2O2S:Eu3+, emit bright luminescence with high quantum efficiency (60,000 photons per
MeV for bulk Gd2O2S:Eu3+), when excited by ionizing radiation such as X-Ray, UV, or
beta-radiation. Luminescence, especially in the red range of wavelengths, is highly suitable
for imaging through tissue.[1] In this dissertation luminescence intensity has been used as a
quantitative indicator for radiolabeled drug concentration, and as an indicator of pH when
paired with appropriate dye combinations.
In chapter 2 we demonstrated a method to image and quantify radiolabeled drug
release from a biomedical implant surface using a radioluminescent polymer film
composite and CCD camera. We applied this general method in measuring beta-emitting,
3

H-vancomycin concentration on the surface of a locking compression plate conformally

coated with Gd2O2S:Eu3+ radioluminescent microparticles. Radioluminescence increases
linearly with concentration of 3H-vancomycin (R2=0.99). As drug is released from the
implant surface we are able to quantitatively measure the amount remaining by comparing
luminescence changes in the analyte modulated region to a luminescent control region with
a known amount of encapsulated 3H.[2]
Monitoring antibiotic release (or accumulation) at the implant surface is useful
because biofilm related infections are not usually eradicated with traditional administration
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of intravenous or oral antibiotics.[3,4] There is a significant amount of research in
developing drug/device combinations that will effectively prevent and/or treat implant
associated infection[5–8], but the ability to monitor that drug release in the body is of equal
importance. Drug release, in any treatment paradigm, needs to be within a therapeutic
dosage window to be effective.[9] As a result, this method may be useful in combination
with polymer-based drug release strategies that have already been designed for a variety of
different diseases (i.e. prostate cancer[10], breast cancer, Alzheimer’s[11], malignant brain
tumors[12], osteosarcoma[13], glioblastomas[14], and hepatomas[15]). An advantage of the
described approach is the use of tritium as an analyte label. Hydrogen atoms are ubiquitous
in any carbon-based structure, which includes most drug molecules. Incorporation of 3H
should not interfere with drug action and provides an analyte specific label for tracking via
radioluminescence. The primary hurdle for generalizing this method for alternative implant
drug release applications will be the incorporation of radioluminescent material.
The ability to monitor drug release from biomedical implant surfaces is of great
importance, but nanomaterials for targeted drug delivery also tend to lack quantitative, in
vivo, monitoring capability. In chapter 3 we extended the work done in chapter 2 to provide
proof of principle for monitoring drug release using radioluminescent nanoparticles and
radiolabeled drugs. Again, the drug release motif tackled in this work targets implant
associated infection. Sodium fluoride (NaF) doped Gd2O2S:Eu3+ nanoparticles are
synthesized and successfully functionalized with silane-PEG5000-biotin. Antivancomycin IgM is streptavidin labeled for direct attachment of antibodies to biotin labeled
nanoparticles. In dried samples of Gd2O2S:Eu3+ nanoparticles, there is a linear response
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between luminescence intensity and concentration of 3H-vancomycin. Nanoparticles in
aqueous suspension did not display the same luminescence response, but this is likely due
to unsuccessful functionalization with anti-vancomycin IgM. If anti-vancomycin is not
attached to the nanoparticles, we do not expect 3H-vancomycin to bind, and would not
expect a luminescence signal.
While the luminescence response of synthesized nanoparticles to 3H-vancomycin
is incredibly sensitive (LOD=7.8 nCi=0.4 ng vancomycin), the response needs to be
demonstrated and characterized in aqueous suspension to be useful for in vivo application.
For this reason, the functionalization strategy is the first point of improvement in this
project. A simple approach to address this is layer-by-layer alternating deposition of
complementary biodegradable polymers (e.g. polyethylene glycol, polysorbate 80,
polylactic acid, polyethyleneimine, sodium alginate, or poly-co-glycolide) mixed with
radiolabeled analyte.[16–18] For example, negatively charged sodium alginate (AL), and
positively charged polyethyleneimine has been coated onto nanoparticles to prevent fusion
during annealing, and addition of 3H labeled analyte would be a simple modification.[19] In
theory, this simple coating mechanism will bring 3H-analyte in close enough proximity to
the nanoparticles to excite luminescence.
Using radioluminescent materials to quantitatively monitor drug release has been
the primary objective for chapters 2 and 3, while chapter 4 describes the use of
mechanoluminescence for measurement of pH. Bacterial metabolic fermentation produces
lactic and carbonic acid through the glycolysis pathway and, as a result, local acidosis is
an indication of bacterial infection in vitro.[20] Development of a sensor that can probe the
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biochemical environment at the implant surface can be used in tandem with drug release
coatings to evaluate treatment efficacy. In chapter 4 we describe the design of ultrasound
luminescent, pH sensitive films, which are imaged using a stationary ultrasound excitation
source and collection optics. SrAl2O4:Eu, Dy emits luminescence, with a maximum at ~522
nm, and the emission can be red shifted using either KrylonTM fluorescent spray paint or
Nile red fluorescent dye. By red shifting the emission spectrum of SrAl2O4:Eu, Dy, pH
sensitive bromothymol blue modulates the luminescence intensity as pH changes between
4-8.
One drawback for ultrasound luminescent chemical imaging, as currently designed,
is that SrAl2O4:Eu, Dy (and any mechanoluminescent phosphor) requires UV charging
prior to ultrasound imaging. Ultrasound does not directly excite the mechanoluminescent
film, to our knowledge, but serves to release trapped electron hole pairs. Release of these
trapped electrons (and holes) results in luminescence emission, but the “trapping” process

Figure 5.1. a) Ultrasound excited luminescence of SrAl2O4:Eu, Dy embedded in PDMS. Plots show film
behavior as ultrasound is pulsed on and off, after initial excitation with UV (395 nm). b) Ultrasound excited
luminescence of Gd2O2S:Eu embedded in PDMS. Plots show film behavior as ultrasound is pulsed on and
off.
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occurs after initial excitation, e.g., from UV/Visible light.[21–23] This sensor is designed for
use in vivo, and incorporating a UV excitation source poses a significant challenge.
Alternatively, we are investigating the possibility that 3H can serve as an encapsulated
excitation source for mechanoluminescent SrAl2O4:Eu, Dy. This would provide a
consistent, internal, excitation source and permit ultrasound imaging without prior UV
excitation.
There is reason to suspect that mechanoluminescent phosphors, such as
SrAl2O4:Eu, Dy, may be excited by beta radiation. Radioluminescent Gd2O2S:Eu has
exhibited mechanoluminescence when exposed to a focused ultrasound source (Figure
5.1). Both SrAl2O4:Eu, Dy and Gd2O2S:Eu phosphoresce after exposure to UV, and release
luminescence as a direct response to mechanical stimuli (i.e., ultrasound). Besides using
3

H as an internal excitation source to improve pH sensor design, we also plan to image

radiolabeled drug release using the ULCI scanning setup. The changes in luminescence
intensity can be imaged, point by point, using pulsed ultrasound excitation. In this way, the
individual imaging modalities developed in this work may be combined.
Overall, radio- and mechanoluminescent phosphors hold promise in design and
development of chemical sensing for biomedical application. The various mechanisms that
illicit luminescence in phosphorescent materials are still being investigated. With
improvements in light collection, sensor design, and functionalization strategies, the
application potential for biomedical application of phosphorescent materials in boundless.
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Appendix A
MATLAB Analysis: Signal vs. Concentration/Dose

Figure A-1: Luminescence image acquired with IVIS Lumina, displayed in MATLAB. X and Y axes
represent pixel number. Color bar represents luminescence intensity, scale adjusted to 1000-3000 counts.
Fracture fixation plate oriented diagonally with highest 3H-vancomycin concentration in the upper left-hand
corner, decreasing toward the lower right-hand corner.

Use Data Tips in Matlab to determine ROIs:
S_01) X: 35, 65

Y: 40, 70

S_02) X: 65, 95

Y: 60, 90

S_03) X: 85, 115

Y: 90, 120

S_04) X: 110, 140

Y: 105, 135
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S_05) X: 135, 165

Y: 130, 160

S_06) X: 165, 195

Y: 150, 180

S_07) X: 180, 210

Y: 170, 200

S_08) X: 205, 235

Y: 190, 220

S_B) BLANK (left tip of implant) X: 19, 49

Y: 20, 50

S_RL) Background Left Side

X: 30, 60

Y: 175, 205

S_RR) Background Right Side

X: 170, 200

Y: 30, 60

For Matlab Code list values as (Y1:Y2,X1:X2):
ex)

S_01=sum(sum(I_01(40:70, 35:65)));

Figure A-2: ROIs selected for image analysis, displayed as images.
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CODE:
% To open and display the image of interest (as shown in Figure A-1)
% caxis can be adjusted based on luminescence intensity of image
>>A=imread(‘filename’);
>>figure; imagesc(A)
>>caxis([1000 3000])
% Determine regions of interest (ROIs) using data tips feature once image is plotted
% Sum feature will add the total counts from each pixel within the defined ROI
>> S_01=sum(sum(I_01(40:70,35:65)))
S_01 =
1374866
>> S_02=sum(sum(I_01(60:90,65:95)))
S_02 =
1276802
>> S_03=sum(sum(I_01(90:120,85:115)))
S_03 =
1198175
>> S_04=sum(sum(I_01(105:135,110:140)))
S_04 =
1165293
>> S_05=sum(sum(I_01(130:160,135:165)))
S_05 =
1152091
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>> S_06=sum(sum(I_01(150:180,165:195)))
S_06 =
1141685
>> S_07=sum(sum(I_01(170:200,180:210)))
S_07 =
1137329
>> S_08=sum(sum(I_01(190:220,205:235)))
S_08 =
1135057
>> S_B=sum(sum(I_01(20:50,19:49)))
S_B =
1134198
>> S_RL=sum(sum(I_01(175:205,30:60)))
S_RL =
1131240
>> S_RR=sum(sum(I_01(30:60,170:200)))
S_RR =
1131713
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Appendix B
MATLAB Analysis: Drug Release

Figure B-1: Luminescence image acquired with IVIS Lumina, displayed in MATLAB. X and Y axes
represent pixel number. Left-most image depicts primary drug release image without tissue, with insets
depicting analyzed ROIs (30 x 30 pixels). Right-most image depicts primary drug release image through 5
mm tissue, with insets depicting analyzed ROIs (50 x 50 pixels). Color bars represent luminescence intensity,
scale adjusted to 1000-3000 counts (on the left), and 1200-1500 (on the right).

Use Data Tips in MATLAB to determine ROIs
No Tissue: 30 x 30 pixel ROIs
Drug Release:

X(110, 140)

Y(90, 120)

Reference:

X(110, 140)

Y(122, 152)

Constant Drug:

X(110, 140)

Y(155, 185)

Background:

X(40, 70)

Y(100, 130)

5 mm Tissue: 50 x 50 pixel ROIs
Drug Release:

X(100, 150)

Y(80, 130)

Constant Drug:

X(100, 150)

Y(145, 195)

Background:

X(200, 250)

Y(1, 51)
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For MATLAB Code list values as (Y1:Y2,X1:X2):
ex)

S_01=sum(sum(I_01(90:120, 110:140)));

CODE:
% To open and display the image of interest (as shown in Figure B-1)
% caxis can be adjusted based on luminescence intensity of image
>>I_dr01=imread(‘filename’);
>>figure; imagesc(I_dr01)
>>caxis([1000 3000])
% Determine regions of interest (ROIs) using data tips feature once image is plotted
% Sum feature will add the total counts from each pixel within the defined ROI
% 3 images taken at each drug release point. This set of code is repeated for each set of 3
images for every drug release point, with and without tissue
%NO TISSUE
>> S_DR=sum(sum(I_dr01(122:152,110:140)))
S_DR =
1145889
>> S_REF=sum(sum(I_dr01(122:152,110:140)))
S_REF =
1145889
>> S_DR=sum(sum(I_dr01(90:120,110:140)))
S_DR =
1510714
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>> S_REF=sum(sum(I_dr01(122:152,110:140)))
S_REF =
1145889
>> S_CON=sum(sum(I_dr01(155:185,110:140)))
S_CON =
1367173
>> S_BG=sum(sum(I_dr01(100:130,40:70)))
S_BG =
1136172
%5 MM TISSUE
>> S_5DR=sum(sum(I_tis01(80:130,100:150)))
S_5DR =
3407745
>> S_5CON=sum(sum(I_tis01(145:195,100:150)))
S_5CON =
3278816
>> S_5BG=sum(sum(I_tis01(1:51,200:250)))
S_5BG =
3090638
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Appendix C
MATLAB Analysis: Analysis of Blank Regions for LOD

Figure C-1: Luminescence image acquired with IVIS Lumina (120 s exposure), displayed in MATLAB. X
and Y axes represent pixel number. Primary drug release image with additional blank regions coated along
the length of the plate. Insets depicting analyzed ROIs (30 x 30 pixels). Color bars represent luminescence
intensity, scale adjusted to 0-4000 counts for main image, 1180-1350 for drug release and constant regions,
and 1180-1200 for blanks and background.

Use Data Tips in MATLAB to determine ROIs (30x30 pixels)
Drug Release:

X(119, 149)

Y(11, 41)

Blank 1:

X(119, 149)

Y(42, 72)

Constant Drug:

X(119, 149)

Y(74, 104)

Blank 2:

X(119, 149)

Y(105, 135)
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Blank 3:

X(119, 149)

Y(139, 169)

Blank 4:

X(119, 149)

Y(170, 200)

Blank 5:

X(119, 149)

Y(205, 235)

Background:

X(25, 55)

Y(70, 100)

For MATLAB Code list values as (Y1:Y2,X1:X2):
ex)

S_01=sum(sum(I_lod01(11:41, 119:149)));

CODE:
% To open and display the image of interest (as shown in Figure C-1)
% caxis can be adjusted based on luminescence intensity of image
>>I_lod01=imread(‘filename’);
>>figure; imagesc(I_lod01)
>>caxis([0 4000])
% Determine regions of interest (ROIs) using data tips feature once image is plotted
% Sum feature will add the total counts from each pixel within the defined ROI
% 10 images taken consecutively. This set of code is repeated for each image.
>> S120_1DR=sum(sum(I_lod01(11:41,119:149)))
S120_1DR =
1222609
>> S120_1B1=sum(sum(I_lod01(42:72,119:149)))
S120_1B1 =
1143948
>> S120_1CON=sum(sum(I_lod01(74:104,119:149)))
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S120_1CON =
2244833
>> S120_1B2=sum(sum(I_lod01(105:135,119:149)))
S120_1B2 =
1145970
>> S120_1B3=sum(sum(I_lod01(139:169,119:149)))
S120_1B3 =
1145010
>> S120_1B4=sum(sum(I_lod01(170:200,119:149)))
S120_1B4 =
1145851
>> S120_1B5=sum(sum(I_lod01(205:235,119:149)))
S120_1B5 =
1143093
>> S120_1BG=sum(sum(I_lod01(70:100,25:55)))
S120_1BG =
1135315
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Copyright Permission Concerns
For: G. B. Schober, J. N. Anker, Adv. Funct. Mater. 2022, 32, 2106508.
https://www.wiley.com/network/researchers/latest-content/how-to-clear-permissions-fora-thesis-or-dissertation

150

